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Summary 
Various stimuli that perturb neuronal homeostasis and cause neurodegeneration 
trigger microglia reactivity. The microglia reaction and the increased production 
of pro-inflammatory mediators is intended to protect the central nervous system, 
including the retina, from noxious insults and facilitate a rapid return to normal 
homeostasis. However, sustained and dysregulated microglia inflammatory 
responses can lead to robust neuropathological changes that contribute to the 
severity and progression of neurodegenerative diseases. In the retina, 
pathologically activated microglia have been shown to not only contribute to 
neurodegenerative processes indirectly via the release of neurotoxic substances, 
but also directly via the indiscriminate phagocytosis of stressed but living 
photoreceptors. Consistently, innumerous studies have demonstrated that 
microglial modulation represents an attractive therapeutic avenue to alleviate or 
delay neurodegenerative diseases of the retina. Translocator protein (18kDa) 
(TSPO) located in the outer mitochondrial membrane is acutely and specifically 
expressed in activated microglia during retinal pathology. Importantly, specific 
TSPO ligands have been shown to potently modulate microglia inflammatory 
responses and ameliorate light-induced photoreceptor degeneration in mice. 
However, understanding the regulation of TSPO expression in microglia during 
health and disease is paramount prior to any utilization of this protein as a 
therapeutic target to modulate chronic microglia inflammatory responses and 
alleviate retinal degeneration. The aim of the current study therefore was to carry 
out a detailed functional characterization of the TSPO promoter and identify 
genetic elements and transcription factors responsible for maintaining basal and 
mediating induced TSPO expression in microglia.  
To this end, a 2.812Kb murine Tspo promoter sequence was amplified by PCR 
and cloned into the promoterless pGL4.10-Basic luciferase reporter vector. 
Plasmids containing 5’ unidirectional deletions of the promoter were then 
generated by PCR. BV-2 microglia cells were transfected with the generated 
reporter plasmids for 24 h, and an additional 6 h in the case of lipopolysaccharide 
(LPS) stimulation before measuring luciferase activity. Sequence analysis was 
performed using Matinspector software and site-directed substitution 
   
 
 
II 
 
mutagenesis was used to confirm the functional status of the putative 
transcription factor binding sites. Chromatin immunoprecipitation (ChIP) was 
used to investigate binding of transcription factors to the endogenous promoter. 
The effect of transcription factor knockdown on Tspo promoter activity was 
assessed using RNAi mediated gene silencing followed by transfection with the 
reporter constructs and measurement of luciferase activity 24 h later. 
Additionally, effects of RNAi mediated gene silencing on endogenous Tspo 
protein levels were determined using western blot analysis.  
Deletion mutagenesis indicated that −845 bp upstream of the transcription 
initiation site was sufficient to reconstitute near maximal promoter activity in BV-
2 microglia cells. Deletion of sequences extending -593 to -520, which harbour 
an Ap-1, Ets.2 and Nkx3.1 site which also serves as a non-canonical binding site 
for Sp1-family transcription factors, led to a dramatic decrease in both basal as 
well as LPS induced promoter activity. Further deletion of sequences extending -
168 to -39, which contains four GC boxes, also significantly decreased Tspo 
promoter activity. Site-directed mutagenesis of Ap-1, Ets.2, Nkx3.1/Sp1/3/4 and 
the proximal GC boxes led to significant decreases in promoter activity. ChIP-
qPCR revealed that Pu.1, Ap-1(cJun/cFos), Stat3, Sp1, Sp3 and Sp4 bind the 
endogenous Tspo promoter. Notably, upon LPS stimulation, the binding of these 
factors, with the exception of Stat3, was significantly enhanced. RNAi mediated 
silencing of Pu.1, cJun, cFos, Stat3, Sp1, Sp3 and Sp4 gene expression 
significantly diminished Tspo promoter activity while Ap1(cJun/cFos) silencing 
effectively blocked LPS-induced increase in Tspo protein levels. Taken together, 
these findings demonstrate that the consensus binding sequences for Ap-1, 
Ets.2, distal as well as proximal Sp1/3/4 sites must be intact for maximal basal 
and LPS induced Tspo promoter activity in microglia. Furthermore, the current 
findings indicate that LPS-mediated increase in Tspo expression is mediated, at 
least in part, at the transcriptional level and is accompanied by an enhanced 
recruitment of Pu.1, Ap-1(cJun/cFos), Sp1, Sp3, and Sp4 factors to the Tspo 
promoter.  
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Zusammenfassung 
Verschiedenste Stimuli, welche die neuronale Homöostase stören und 
neurodegenerative Erkrankungen verursachen, führen zur inflammatorischen 
Aktivierung von Mikrogliazellen. Mikrogliaaktivierung und die erhöhte Freisetzung 
von pro-inflammatorischen Signalmolekülen dienen ursprünglich dem Schutz des 
zentralen Nervensystems, inklusive der Netzhaut, vor schädlichen Einflüssen 
und ermöglichen ein rasches Wiederherstellen der gesunden Homöostase. 
Dauerhafte und fehlregulierte inflammatorische Reaktivität von Mikrogliazellen 
führt hingegen zu auffälligen neuropathologischen Veränderungen, welche die 
Schwere und den Verlauf neurodegenerativer Erkrankungen negativ verstärken 
können. In der Netzhaut tragen pathologisch aktivierte Mikroglia nicht nur 
indirekt, durch die Ausschüttung neurotoxischer Substanzen, sondern auch 
direkt, durch die fehlgesteuerte Phagozytose von geschädigten aber noch 
lebenden Photorezeptorzellen, zum verschlechterten Krankheitsverlauf bei. Auf 
diesen Beobachtungen basierend, demonstrierten bereits zahlreiche Studien die 
Modulation der Mikrogliaaktivität als vielversprechenden therapeutischen Weg 
um neurodegenerative Erkrankungen der Netzhaut zu mildern oder zu verzögern. 
Das Translokatorprotein (18 kDa) (TSPO) befindet sich in der äusseren 
Mitochondrienmembran und ist selektiv in reaktiven Mikrogliazellen während 
verschiedenen Netzhautdegenerationen verstärkt exprimiert. Interessanterweise 
konnte bereits nachgewiesen werden, dass spezifische TSPO Liganden in der 
Lage sind die pro-inflammatorische Mikrogliaaktivierung zu modulieren und 
dadurch die lichtinduzierte Photorezeptordegeneration im Mausmodell zu 
reduzieren. Das klare Verständnis der Regulation der TSPO Expression in 
Mikrogliazellen während Homöostase und Krankheit stellt eine 
Grundvoraussetzung für die Nutzung des Proteins als therapeutisches target im 
Kontext der Mikrogliaaktivierung und Netzhautdegeneration dar. Daher war das 
Ziel der vorliegenden Studie eine detaillierte funktionelle Charakterisierung des 
TSPO Promotors sowie die Identifikation von genetischen Elementen und 
Transkriptionsfaktoren, welche für die basale sowie induzierbare TSPO 
Expression in Mikrogliazellen verantwortlich sind. Zu diesem Zwecke wurde eine 
2,812 kb grosse murine Tspo Promotorsequenz mittels PCR amplifiziert und in 
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den promotorlosen pGL4.10-Basic Luciferase Reporter Vektor kloniert. Als 
nächstes wurden durch PCR einzelne Plasmide mit 5` Deletionen verschiedener 
Längen generiert. BV-2 Mikrogliazellen wurden mit den so erhaltenen 
Reporterplasmiden für 24 h transfiziert und nach weiterer sechsstündiger 
Inkubation mit Lipopolysaccharid (LPS) die Luciferaseaktivität gemessen. 
Sequenzanalyse wurde mittels der Software MatInspector ausgeführt und 
zielgerichtete Mutagenese PCR wurde angewandt um die Funktionalität der 
putativen Transkriptionsfaktorbindestellen nachzuweisen. Die tatsächliche 
Bindung verschiedener Transkriptionsfaktoren an den endogenen Promotor 
wurde mittels Chromatin Immunpräzipitation (ChIP) experimentell belegt. RNAi-
vermittelte Gen-Silencing Experimente wurden zur Untersuchung des Effekts von 
Transkriptionsfaktor Knock-Down auf die Luziferaseaktivität der 
Reporterkonstrukte durchgeführt. Zusätzlich wurde die endogene Tspo Protein 
Menge nach diesen RNAi Gen-Silencing Experimenten mittels Western Blot 
analysiert. Unsere Mutageneseexperimente belegten, dass ein Abschnitt von -
845 bp upstream der Transkriptionsinitiationsstelle für nahezu maximale 
Promotoraktivität in BV-2 Mikrogliazellen ausreichend ist. Die Deletion des 
Sequenzbereichs zwischen -593 und -520, welcher sowohl eine Ap-1, Ets.2 als 
auch Nkx3.1 Bindestelle - die auch als Bindestelle für Transkriptionsfaktoren der 
Sp1-Familie fungiert – enthält, führte zu einem drastischen Verlust sowohl der 
basalen als auch LPS induzierten Promotoraktivität. Des Weiteren führte die 
Deletion des Sequenzbereichs von -168 bis -39, welcher vier GC Boxen enthält, 
ebenfalls zu einem signifikanten Abfall der Tspo Promotoraktivität. Analog dazu 
führte die zielgerichtete Mutagenese der AP-1, Ets.2, Nkx3.1/Sp1/3/4 und 
proximalen GC Boxen ebenfalls zu starken Abschwächungen der 
Promotoraktivität. ChiP-qPCR Experimente belegten anschliessend die 
tatsächliche physikalische Bindung der Faktoren Pu.1, Ap-1(cJun/cFos), Stat3, 
Sp1, Sp3 und Sp4 am endogenen Tspo Promotor. Bemerkenswerterweise war 
die Bindung aller dieser Faktoren (mit Ausnahme von Stat3) nach LPS-
Stimulation siginifikant verstärkt. RNAi-vermitteltes Gen-Silencing von Pu.1, 
cJun, cFos, Stat3, Sp1, Sp3 und Sp4 reduzierte die Tspo Promotoraktivität 
signifikant, wohingegen ein Silencing von Ap1(cJun/cFos) effektiv die LPS 
vermittelte Tspo Induktion blockierte. Zusammenfassend demonstrieren unsere 
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Ergebnisse, dass die Konsensusbindesequenzen für Ap-1, Ets.2 und der distalen 
wie proximalen Sp1/3/4 Bindestellen für maximale basale und LPS induzierte 
Tspo Promotor Aktivität in Mikrogliazellen vorhanden und intakt sein müssen. 
Zusätzlich deuten unsere Ergebnisse darauf hin, dass der LPS induzierte Anstieg 
der Tspo Expression zumindest teilweise auf dem transkriptionellen Weg 
vermittelt wird und mit einer erhöhten Rekrutierung der Transkriptionsfaktoren 
Pu.1, Ap-1(cJun/cFos), Sp1, Sp3, und Sp4 zum Tspo Promotor einhergeht. 
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1.0 Introduction 
1.1 The Retina 
The sensory retina is a subtle, 200 µM thick central nervous tissue lining the back 
of the eye and whose structure is evolutionary conserved (Masland, 2012). It 
consists of more than 60 different functional cell types that come in a wide 
collection of shapes and sizes (Masland, 2001). Retinal cells are highly ordered 
into anatomical layers where cellular nuclei and neuronal processes are distinctly 
segregated (Forrester et al., 2015). The innermost layer of the retina near the 
vitreous is the ganglion cell layer (GCL) which contains the cell bodies of the 
retinal ganglion cells (RGCs). Electrical signals are transmitted from 
photoreceptors to RGCs via bipolar cells in the inner plexiform layer (IPL) 
(Wässle, 2004). However, some bipolar cells do not transmit signals directly to 
RGCs, but rather form synapses with amacrine cells which subsequently transmit 
these visual signals to dendrites of RGCs within the IPL (Masland, 2012). 
Amacrine cells which are inhibitory interneurons function to modulate signals 
reaching ganglion cells (Forrester et al., 2015). RGCs then relay the collected 
visual signals from bipolar and amacrine cells to the brain via their axons which 
bundle together to form the optic nerve (Tian and Copenhagen, 2003). Thus, the 
RGCs make up the primary output units of the retina and inform the brain 
everything it knows about the content of the visual world (Dhande and Huberman, 
2014). 
Adjacent to the GCL is the IPL, one of the two major synaptic layers found in the 
vertebrate retina (Koontz and Hendrickson, 1987). This layer is composed of 
multiple strata where intricate synaptic connections between processes of 
different types of bipolar cells, RGCs and amacrine cells can be found (Wässle, 
2004). The IPL is also broadly subdivided into two functionally discrete 
sublaminae termed as sublamina “a” and “b” (Wässle, 2004). The axons of “OFF” 
bipolar cells terminate in sublamina “a” (outer half) of the IPL where they make 
contact with “OFF” retinal ganglion cell arbors, whereas “ON” bipolar cells 
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terminate in sublamina “b” (inner half) and make contact with “ON” ganglion cells 
(Wässle, 2004). This bisublaminar organization of the IPL is designed to separate 
“ON” and “OFF” channels in retinal ganglion cells (Kolb and Famiglietti, 1974). 
The next layer is the inner nuclear layer (INL), composed of nuclei from bipolar, 
amacrine and horizontal cells. The nuclei are oriented such that those of 
horizontal cells are located next to the outer plexiform layer (OPL) whereas those 
of the amacrine cells are located next to the inner plexiform layer (Forrester et 
al., 2015). Such an organization allows amacrine and horizontal cells to make 
synaptic contacts with RGCs and photoreceptors respectively with ease 
(Forrester et al., 2015). The bipolar cells in the INL pass their dendrites outwards 
to synapse with the rod spherules and cone pedicles in the OPL and relay their 
signals to the RGCs and amacrine cells in the IPL (Masland, 2012). Similarly, the 
horizontal cells in the INL, which are second order neurons in the retina, extend 
wide spreading lateral processes to the OPL where they make synaptic 
connections with the axon terminals of cone and rod photoreceptors (Strettoi and 
Masland, 1995). These horizontal cells in most vertebrate retinas can be 
categorized into two morphological forms; a Type A which is a large axon-less 
cell with stout dendritic processes that makes contact exclusively with cones, and 
a Type B which is smaller in size and bears, in addition to dendritic ends that 
contact cones, an extensive 300 µM axon that contacts exclusively rods (Boije et 
al., 2016). Horizontal cells, like amacrine cells, function as inhibitory neurons to 
modulate synaptic transmission between photoreceptors and bipolar cells (Chaya 
et al., 2017). Therefore, the outer plexiform layer can be termed as a as a layer 
of synapses where glutamatergic neurotransmission occurs between 
photoreceptors and bipolar cells, with the horizontal cells playing an integrative 
role in photoreceptor signal processing via the release of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) (Wu, 2010). 
The photoreceptor layer lies in the outermost part of the retina. The two types of 
photoreceptor cells, rods and cones, have a basic structure composed of four 
morphologically distinguishable compartments namely outer segment, inner 
segment, a nucleus and a synaptic terminal that contacts bipolar and horizontal 
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cells in the OPL (Sung and Chuang, 2010). The outer segment (OS) lies adjacent 
to the retinal pigment epithelium (RPE) and is composed of cylindrically shaped 
membranous disks that are synthesized at the base of the OS (Forrester et al., 
2015). Once synthesized, the disks travel over a course of around 10 days to the 
OS tips where they are enclosed by microvilli present on the apical side of the 
RPE (Forrester et al., 2015; Wright et al., 2010). Older disks are continuously 
shed from the OS tips in a circadian fashion and phagocytosed by the RPE 
(Forrester et al., 2015; Wright et al., 2010). The inner segment (IS), connected to 
the OS via a modified cilium, contains the major metabolic and biosynthetic 
machinery of the cell including the mitochondria, endoplasmic reticulum, Golgi 
complex and lysosomes (Molday and Moritz, 2015). The OS are incapable of 
synthesizing membrane proteins required for phototransduction, and therefore 
once produced in the IS, these proteins have to be trafficked to the OS via a 
connecting cilium (Molday and Moritz, 2015). Failure of connecting cilium function 
has been implicated in many retinal diseases including retinitis pigmentosa and 
Leber congenital amaurosis (Adams et al., 2007). The nuclei of the 
photoreceptors are tightly stacked in the ONL, with cone nuclei forming just a 
single row beneath the outer limiting membrane and rod nuclei making up the 
remainder (Molday and Moritz, 2015; Mustafi et al., 2009). Of note is that out of 
the different photoreceptor compartments, the light-sensitive photopigments are 
contained in the outer segments which lie furthest from the path of incoming light 
(Figure 1) (Masland, 2001). Rods, responsible for scotopic vision, contain 
rhodopsin in their OS as the light sensitive pigment whereas cones posses one 
of three different types of cone opsins in their OS to mediate photopic vision 
(Mustafi et al., 2009). Light must pass through vitreous humor and the different 
layers of the retina before it can be captured and converted into chemical signals 
by the photoreceptors (Masland, 2001, 2012).   
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Figure 1: Cellular organization of the mammalian retina. A) Schematic 
representation of the human eye showing the posterior location of the retina. B) Simple 
schematic diagram of the cellular and synaptic organization of the vertebrate retina C) 
Representative cross-section of the human neural retina, the retinal pigment epithelium 
and the choroidal vessels showing the highly ordered arrangement of retinal layers. A) 
modified from (Rajala and Gardner, 2016), (B) schematic representation of the retina 
modified from (Reyes et al., 2017), choroid adopted from (Akhtar-Schäfer et al., 2018) 
(C) modified from (Wright et al., 2010).  
In addition, and similar to other parts of the nervous system, neuronal cells in the 
retina are found in intimate apposition to glia cells (Reichenbach and Robinson, 
1995). Three morphologically distinct glia cells types can be identified in the 
mammalian retina including Müller cells, astrocytes and microglia (Vecino et al., 
2016). Müller cells, first described by Heinrich Müller in 1851 as radial fibres, are 
the predominant glial cells in the retina representing approximately 90% of the 
retinal glia population (Forrester et al., 2015; Vecino et al., 2016). They are the 
only cells that span the entire depth of the neural retina, radiating from the outer 
limiting membrane where they form adherens junctions with photoreceptor inner 
segments to the inner limiting membrane where their expanded end-foot 
terminate (Forrester et al., 2015; Newman and Reichenbach, 1996). They are 
seen to wrap neuronal somata and axons in an insulating sheath, helping 
maintain neuronal function by providing neuronal termini with nutrients and 
neurotransmitter precursors (Vecino et al., 2016). Moreover, Müller cells support 
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neuronal survival and function by releasing trophic factors, recycling 
neurotransmitters and controlling ionic balance in the extracellular space 
(Bringmann et al., 2009; Goldman, 2014; Pow and Crook, 1996). Retinal 
astrocytes on the other hand are predominantly located in the nerve fibre layer 
where their processes join to form a honeycomb structure (Ramírez et al., 1998). 
They perform similar functions to Müller cells including extracellular ion balance 
and neurotrophic, metabolic and mechanical support of neurons (Vecino et al., 
2016). They also constitute a key functional component of the blood-retina 
barrier, which is essential in maintaining retinal homeostasis (Ramírez et al., 
1998; Vecino et al., 2016). The third group of retinal glial cells, microglia, 
constitute the primary immune cell type in the retina and morphologically 
resemble those found throughout the CNS with their highly branched and 
dynamic protrusions (Langmann, 2007; Silverman and Wong, 2018). They are 
regarded as immunological watchdogs in the healthy retina, where they fulfil 
diverse tasks of surveillance (Karlstetter et al., 2015).   
1.2 Retinal microglia   
Microglial cells, distributed in the GCL, IPL and OPL layers, form an integral part 
of the innate immune defense system in the retina (Chen and Xu, 2015). They 
are equipped with a host of surface receptors and filopodia-like processes that 
constantly extend and retract to allow them efficiently monitor the surrounding 
microenvironment (Karlstetter et al., 2015). In addition, microglia housekeeping 
activities such as phagocytic removal of cellular corpses and debris and sculpting 
of synaptic circuits helps maintain a conducive retinal environment for the healthy 
functioning and survival of neurons (Linnartz and Neumann, 2013; Schafer et al., 
2012; Wong, 2013). In the presence of tissue damaging stimuli, microglia cells 
respond by undergoing rapid proliferation and migration to the site of injury where 
they release a host of proinflammatory mediators aimed at neutralizing the 
noxious insult (Rashid et al., 2018c; Scholz et al., 2015c). However, while much 
is known about the major pathways involved in microglia activation and 
proinflammatory responses, it was not until recently when the expansion and 
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renewal mechanisms of microglial cells in the retina were uncovered (Elmore et 
al., 2014; Huang et al., 2018). 
1.2.1 Origin and maintenance of microglia in the retina  
Over several decades, questions lingered as to whether myeloid cell populations 
in the CNS including retina were renewed by in-situ proliferation of resident 
microglia or whether bone marrow (BM) derived macrophages could also migrate 
to the healthy CNS tissue and readily differentiate into functional microglia 
(Simard and Rivest, 2004). To address this question, earlier studies used bone 
marrow (BM) chimeras obtained by transplantation of labelled BM derived cells 
from a transgenic donor animal to a recipient that has been lethally irradiated to 
ablate BM cells (Ransohoff, 2007). Xu and colleagues used this protocol to 
adoptively transfer BM derived cells expressing enhanced green fluorescent 
protein (eGFP) from eGFP-transgenic mice into lethally irradiated normal adult 
mice and waited for 8, 14- and 26-weeks prior to sacrificing the animals (Xu et 
al., 2007). Retinal flatmounts from the recipient mice revealed that BM derived 
eGFP+ cells could be detected in the retina as early as 8-weeks post 
transplantation, and by the 6th month, the entire retinal myeloid cell population 
was eGFP+ (Xu et al., 2007). A separate study using Cx3cr1-gfp/+ knock-in mice 
as BM donors, where eGFP protein expression is restricted to cells of the 
monocyte lineage, observed recruitment of eGFP+ monocyte-derived cells into 
recipient retinas just 4 weeks post-transplantation (Kezic and McMenamin, 2008). 
The authors attributed the earlier appearance of eGFP+ donor cells observed in 
their study, as opposed to that of Xu et al., to differences in chimera models 
(global eGFP mice vs. Cx3cr1-gfp/+) and blood retinal barrier (BRB) integrity 
between the mouse strains (Kezic and McMenamin, 2008). Of note is that both 
studies observed very little in-situ proliferation of the resident microglia under 
steady state conditions and therefore concluded that a majority of the 
microglia/macrophages in the retinal tissue were replenished from BM derived 
monocyte precursor cells (Kezic and McMenamin, 2008; Xu et al., 2007). In 
contrast, findings from a different study where irradiated mice were injected with 
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eGFP+ BM derived cells showed that a very small number of eGFP+ cells 
accessed the uninjured healthy retina up to 12 months post transplantation, 
despite a large number of them accumulating in surrounding ocular tissues such 
as the ciliary body, RPE, choroid and the optic nerve head (ONH) (Kaneko et al., 
2008). However, in response to the neurotoxic agent N-methyl-N-nitrosourea that 
induces retinal degeneration, numerous eGFP+ BM derived cells could be 
detected in the retina, implying that the recruitment of BM-derived microglia in the 
retina occurs almost exclusively under retinal damage (Kaneko et al., 2008). 
Interestingly, the authors argued that the enhanced migration of BM-derived cells 
to the retina observed in the previous studies might have been prompted by an 
unintentional damage of retinal neurons and vasculature as a result of not 
shielding the eyes and heads of experimental animals during irradiation (Kaneko 
et al., 2008). This line of thought was in fact consistent with previous findings 
which had demonstrated that rats exposed to X-ray doses between 200-500 cGy 
(compared to 800-1000 cGy used in the aforementioned studies) exhibited 
structural abnormalities in the retina characterized by damaged rod 
photoreceptor outer segment membranes and swollen or ruptured mitochondria 
in the RPE (Amoaku et al., 1989). Nonetheless, while the arguments from Kaneko 
et al. were accurate, they were somehow understated and failed to capture other 
flaws of the irradiation experimental protocol that might have biased the system 
towards a non-physiological transmigration of eGFP+ cells to the CNS: Firstly, 
irradiation induced bone marrow ablation is associated with enormous fluxes of 
cytokines through circulation and in tissue which subsequently cause disruptive 
changes to the blood brain barrier (BBB) (Ransohoff, 2007; Varatharaj and Galea, 
2017); Secondly, irradiation of the CNS induces vascular perturbations that affect 
the competence of the BBB (Figure 2) (Greene-Schloesser et al., 2012; 
Ransohoff, 2007).  
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Figure 2: Irradiation weakens the integrity of the blood brain barrier. To investigate 
whether bone marrow (BM) derived microglia precursors are recruited to the healthy 
CNS, animals are exposed to irradiation to kill their bone-marrow cells. These are then 
replaced with labeled ones derived from a transgenic animal. Irradiation induced 
apoptosis of BM cells elicits a strong immune response characterized by enormous 
fluxes of cytokines through the circulation and in tissues. In addition, CNS exposure to 
irradiation causes vascular changes that compromise the integrity of the blood-brain 
barrier. Such experimental confounds associated with irradiation, and in particular, high 
amounts of circulating cytokines, can lead to the non-physiological transmigration of BM 
cells into the CNS which can give rise to microglia-like cells. Figures adopted and 
modified from (Ginhoux and Garel, 2018; Ransohoff, 2007).  
Therefore, to further assess whether BM-derived microglia precursors are 
recruited to the healthy CNS while circumventing the problems associated with 
irradiation, a subsequent study used parabiosis experiments (Ajami et al., 2007). 
Parabiosis, a surgical technique that fuses the vasculature of two living 
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organisms, allowed for the sharing of the blood circulation between wild type and 
GFP transgenic mice without affecting their blood-brain nor the blood-retinal 
barrier (Ajami et al., 2007; Kamran et al., 2013). Five months post-surgery, no 
GFP+ microglia could be detected in sections obtained from the brain, brainstem 
or the spinal cord, indicating that under steady-state conditions, CNS microglia 
were a closed system with the capacity to self-renew and that their maintenance 
was independent of BM-derived circulating progenitors (Ajami et al., 2007). 
Furthermore, the authors observed that when facial motoneuron injury was 
induced in both parabiotic pairs and irradiated/transplanted mice, exogenous 
GFP+, Iba-1+, BM-derived microglia cells could only be detected in the 
irradiated/transplanted groups, strongly corroborating earlier findings that the 
replacement of microglia by circulating precursors can be induced by 
experimental manipulations associated with irradiation (Ajami et al., 2007). In a 
subsequent landmark study, Ginhoux et al. established that microglia residing in 
the adult CNS in the steady state are derived from primitive myeloid progenitors 
that migrate from the yolk sac into the brain by embryonic day 9.5, after which 
the BBB forms and effectively blocks postnatal hematopoietic progenitors from 
contributing to microglia maintenance (Ginhoux et al., 2010).  
To further examine whether microglia renewal and expansion occurred solely 
from local resident cells, Elmore et al. used an inhibitor of colony stimulating 
factor 1 receptor (CSF1R), PLX3397, to deplete microglia cells in the brain 
without compromising the integrity of the BBB (Elmore et al., 2014). Findings from 
the study demonstrated that the brain harbored latent nestin+ microglial 
progenitors, which following microglia depletion in the brain, undergo rapid 
proliferation and differentiation to repopulate the entire brain within 1 week of 
inhibitor cessation (Elmore et al., 2014). Notably, the observed regeneration of 
microglia in the depleted brain mirrored some aspects of normal development, as 
embryonic stem cells similarly require a nestin+ stage on their way to becoming 
microglia (Elmore et al., 2014; Hughes and Bergles, 2014). These findings raised 
the question whether retinas depleted of microglia could be repopulated in similar 
fashion from nestin+ precursors (Elmore et al., 2014). To this end, Huang et al. 
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used a selective CSF1R inhibitor, PLX5622, to deplete microglia in the CNS 
including retina and assess the origin of the repopulated microglia (Huang et al., 
2018). In contrast to the brain, the repopulated retinal microglia were not derived 
from nestin+ progenitors, but rather from dual extra retinal origins; residual 
microglia in the optic nerve which repopulated the retina along the center-to-
periphery axis, and macrophages in the ciliary body/iris which repopulated the 
retina along the periphery and accounted for around 15% of the repopulated 
microglia (Huang et al., 2018). Of note is that findings from the study uncovered 
novel radial migratory routes of retinal microglia and demonstrated the presence 
of peripheral macrophage-derived microglia which were significantly less ramified 
than their central counterparts (Huang et al., 2018). 
1.2.2 Microglia in the healthy retina 
Microglia cells play active roles in maintaining normal retinal tissue homeostasis. 
During the course of embryonic development, amoeboid cells immunopositive for 
microglia/macrophage markers invade the retina by crossing the vitreal surface 
and by migrating from nonneural ciliary regions (Santos et al., 2008). These cells 
are largely confined to the inner half of the retina in close proximity to dying RGCs 
which are excessively produced during development (Santos et al., 2008). As 
professional phagocytes, these strategically located amoeboid microglia engage 
in extensive phagocytic clean-up of apoptotic cellular corpses of the RGCs, 
thereby preventing leakage of cellular contents that promote inflammation and 
tissue necrosis (Ravichandran, 2003). Moreover, during the first postnatal days 
when RGC neurons make exuberant synaptic connections to the lateral 
geniculate nucleus (LGN) of the thalamus, microglia cells actively engage in 
pruning of transient, intact retinogeniculate synapses (Schafer et al., 2012). This 
process is dependent upon neural activity, where microglia preferentially engulf 
weak synaptic connections (Schafer et al., 2012). Furthermore, microglia 
mediated synaptic pruning occurs via a complement C3-CR3-dependent 
mechanism, where activated C3 (iC3b/C3b) selectively labels the weak RGCs 
terminals triggering a C3-receptor dependent phagocytosis pathway (Schafer et 
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al., 2012). Indeed, C3 or CR3 knockout mice exhibit striking defects in synaptic 
pruning during development (Schafer et al., 2012). 
Microglia cells in the developing retina also play an essential role in shaping 
vascular development (Silverman and Wong, 2018). Consistent with this role, 
microglia have been demonstrated in rodents and humans to populate the retina 
before developmental vascularization commences (Checchin et al., 2006; Rymo 
et al., 2011). During retinal vascularization, microglial cells are commonly 
associated with endothelial tip-cells at the vascular front and have been shown 
to play an active role in promoting angiogenic sprout anastomosis formation 
(Checchin et al., 2006; Rymo et al., 2011). This process is however independent 
of a direct contact between microglia cells and the vessels, and instead occurs 
via soluble factors secreted by both microglia and vascular endothelial cells 
(Rymo et al., 2011). Soluble factors released by the vasculature attracts 
microglial cells and promotes their release of angiogenic factors (Rymo et al., 
2011). Consequently, the absence of microglia has been demonstrated to alter 
CNS vascularization (Arnold and Betsholtz, 2013). In neonatal rats for example, 
pharmacologic depletion of microglia using clodronate liposomes results in 
pronounced decreases in the retinal vascular area and density (Checchin et al., 
2006). Intriguingly, replenishment of microglia-depleted retinas with exogenous 
microglia restored vascularity in the developing tissue, strongly indicating a 
prominent role for microglia in normal retinal blood vessel formation (Checchin et 
al., 2006). This notwithwithstanding, retinal myeloid cells have also been 
demonstrated to suppress angiogenic branching of deep retinal vessels via a 
Wnt-Flt1 pathway, implying that microglia cells can be either anti-angiogenic or 
pro-angiogenic depending on context (Stefater III et al., 2011).  
The outer retina, from the ONL to the RPE, is an immune privileged zone that 
remains consistently devoid of microglia cells under normal physiological 
conditions (Silverman and Wong, 2018). RPE cells play a prominently role in 
development and maintenance of this immunosuppressive microenvironment 
(Karlstetter et al., 2015; Zamiri et al., 2007). They secrete inhibitory factors such 
as transforming growth factor-β (TGF-β), thrombospondin-1 (TSP-1) and 
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somatostatin (SOM) into the subretinal space that actively blocks the undesirable 
infiltration of microglia and other mononuclear phagocytes into this region 
(Miyajima-Uchida et al., 2000; Pfeffer et al., 1994; Zamiri et al., 2006). During 
adulthood, microglia cells are found distributed as horizontal arrays of cells in the 
IPL and OPL where they exhibit a quiescent phenotype characterized by very 
small somata and extensively ramified processes that are highly dynamic and 
motile in nature (Langmann, 2007). They form a mosaic network of evenly 
distributed non-overlapping cells that allow the neural retina to be continuously 
sampled every few hours by the continuous movement of the microglial 
processes (Damani et al., 2011; Karlstetter et al., 2015). The dynamic movement 
of the processes also serves other housekeeping functions including homeostatic 
regulation of neuronal activity and the elimination of accumulated metabolic 
waste products and cellular debris in the retinal microenvironment (Li et al., 2012; 
Nimmerjahn et al., 2005). In addition, microglia processes which intimately 
intercalate with neuronal axons and dendrites in the healthy retina plexiform 
layers are required for the maintenance of synaptic structure and physiology 
(Wang et al., 2016). Indeed, long-term absence of microglia in the retina results 
in the degeneration of synapses with concomitant progressive deficits in retina’s 
functional response to light (Wang et al., 2016).  
To effectively patrol the retinal environment and limit unnecessary microglia 
activation, microglia cells are equipped with a versatile subset of different cell-
surface proteins that they use to communicate with neighboring neuronal and 
glial cells (Karlstetter et al., 2015; Kierdorf and Prinz, 2013). CD200R is an 
important example of an inhibitory receptor expressed predominantly on retinal 
microglia that actively maintains microglia in a quiescent state when ligated 
(Broderick et al., 2002; Copland et al., 2007). Its ligand, CD200 (previously known 
as OX2), is a membrane glycoprotein that is widely expressed in the retina, 
including in ganglion cells, photoreceptors, vascular endothelium and RPE (Horie 
et al., 2013; Karlstetter et al., 2015; Langmann, 2007). Previous studies have 
demonstrated that CD200 deficient mice exhibit  augmented pro-inflammatory 
responses in experimental animal models of uveoretinitis and wet form of age 
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related macular degeneration (AMD) (Broderick et al., 2002; Copland et al., 2007; 
Horie et al., 2013). In contrast, pharmacological activation of CD200R using an 
agonist monoclonal rat anti-mouse CD200R (DX109) antibody ameliorates 
pathological outcome in optic nerve injury and experimental autoimmune 
uveoretinitis animal models, suggesting that CD200-CD200R interaction could be 
harnessed for therapeutic purposes (Copland et al., 2007; Horie et al., 2013). 
Another inhibitory factor secreted by neurons to inhibit the inflammatory capacity 
of microglia is CX3CL1 (fractalkine), a constitutively expressed cleavable 
chemokine which binds the Gi-protein coupled receptor CX3CR1 on the surface 
of microglia (Wolf et al., 2013). Numerous studies have demonstrated the 
neuroprotective and immunomodulatory role of CX3CL1-CX3CR1 interaction in 
the CNS (Wolf et al., 2013; Zieger et al., 2014). Transplanting mesenchymal stem 
cells engineered to secrete CX3CL1 in the subretinal space of rats exposed to 
high-intensity light to induce retinal degeneration inhibited microglia activation 
and migration to the ONL with concomitant reduction in neuronal demise (Huang 
et al., 2013). Conversely, in retinal degeneration (rd10) mutant mice deficient of 
CX3CR1, significantly greater numbers of reactive microglia were shown to 
infiltrate the ONL and induce a pro-inflammatory milieu that accelerated 
photoreceptor apoptosis and atrophy when compared with CX3CR1-sufficient 
rd10 littermates (Zabel et al., 2016). Of note is that delivery of exogenous 
CX3CR1 to the rd10 mouse eye significantly decreased the density of reactive 
microglia infiltrating the ONL and slowed the rate of neuronal loss, further 
underscoring CX3CL1-CX3CR1 signaling axis as an important regulator of 
microglial reactivity (Zabel et al., 2016). 
Microglia also establish important interactions with Müller cells by exchanging 
functionally significant signals, and this bidirectional communication can act as a 
mediator of neuron-microglia crosstalk during both physiological and 
pathophysiological conditions (Madeira et al., 2015; Wang and Wong, 2014). 
Certain microglia-derived neurotrophic factors such as BDNF and CNTF are 
consistently shown to be neuroprotective for photoreceptor cells despite these 
cells not expressing their receptors (Kirsch et al., 2002; Ugolini et al., 1995; Wen 
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et al., 2008; Wilson et al., 2007). It was later revealed that microglia derived 
neurotrophic factors interact with Müller cells and induce or inhibit the release of 
secondary factors including basic fibroblast growth factor (bFGF), leukemia 
inhibitory factor (LIF) and glial cell line-derived neurotrophic factor (GDNF) that 
could act directly on photoreceptors and mediate survival or apoptosis during 
pathophysiological conditions (Harada et al., 2000, 2002; Shen et al., 2013; Wang 
et al., 2011; Wenzel et al., 2005). Additionally, microglia-Müller cell cross-talk can 
occur via the translocator protein (TSPO; 18kDa) signaling axis, where Müller 
cells release an endogenous TSPO ligand, diazepam binding inhibitor (DBI) 
protein, which binds microglial TSPO and suppresses microglial activation during 
retinal pathology (Wang et al. 2014). 
1.2.3 Microglia in the diseased retina 
When the retina suffers from a noxious insult, an immune response is launched 
by a local defense system that involves the resident microglia cells and the 
complement system (Chen and Xu, 2015). Microglia cells respond to noxious 
stimuli by retracting their filopodia-like processes (Figure 3) and upregulating a 
variety of cell surface molecules including major histocompatibility complex 
(MHC) class I and II antigens and receptors for cytokines and chemokines 
(Jurgens and Johnson, 2012).  
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Figure 3: Microglia morphology in health and disease. Flat-mounts (a & b) and cross-
section (c & d) images of Iba1-positive microglial cells in retinas from wild-type (a & c) 
and Fam161a-deficient mouse model of Retinitis Pigmentosa (b & d). In the healthy 
retina (a & c), microglia cells are found in the IPL, OPL and GCL where they form a 
mosaic network of evenly distributed non-overlapping cells and exhibit a resting but 
surveillant phenotype characterized by very small somata and extensively ramified 
processes. In the diseased retina (b & d), microglia adopt an amoeboid morphology that 
is either completely devoid of processes or has very few unbranched processes. They 
are found in the degenerating ONL and the subretinal space where they not only engage 
in the phagocytic clearance of cellular corpses and debris, but also actively contribute to 
the degenerative processes. Panel (e) 3D images of Iba-1 stained brain sections 
generated using Fiji software (NIH, USA) showing the progressive changes in microglial 
morphology in response to bacterial lipopolysaccharide. Figures a, b & d adopted and 
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modified from (Dannhausen et al., 2018), figure (e) adopted and modified from 
(Martyanova and Tishkina, 2015).  
In addition, microglia alter their transcriptional profiles and undergo a metabolic 
switch from oxidative phosphorylation (OXPHOS) to glycolysis for the rapid 
production of energy necessary to fuel inflammatory events (Tannahill et al., 
2015). Inflammation-induced metabolic rewiring is also crucial for microglial 
cellular proliferation since biosynthetic pathways for nucleotides, amino acids and 
lipid synthesis branch out from glycolysis (Orihuela et al., 2016; Rashid et al., 
2018c). Reactive microglia cells subsequently migrate to the site of injury where 
they produce multiple pro-inflammatory factors including interleukin IL-1β, IL-6, 
IL-15, interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and 
inducible nitric oxide synthase (iNOS) as well as reactive oxygen and nitrogen 
species (RONS) (Crotti and Ransohoff, 2016; Kierdorf and Prinz, 2013).  
Microglia mediated inflammatory processes are aimed at the rapid return of a 
perturbed tissue back to normal homeostasis. However, if the insults persists, 
such as in aging and degenerative diseases of the retina, microglia transition from 
a well-balanced activation state to a hyperreactive state and produce 
exaggerated levels of pro-inflammatory mediators that contribute to tissue 
damage and exacerbate disease severity (Chen and Xu, 2015; Karlstetter et al., 
2015). In AMD for instance, the widespread accumulation of drusen components 
provides a prominent chemoattractant stimulus that attracts microglia to the 
subretinal space (Indaram et al., 2015; Penfold et al., 2001; Rodriguez et al., 
2014). Once in the outer retina, reactive microglia or microglia-derived factors 
induce NLRP3 inflammasome activation in RPE with the concurrent secretion of 
IL-1β and the degeneration of RPE cells via caspase-1-mediated pyroptosis (Ma 
et al., 2009; Madeira et al., 2018; Nebel et al., 2017; Tseng et al., 2013). The 
downstream effects of RPE loss are deleterious, and include choriocapillaris 
attenuation and secondary photoreceptor demise which ultimately result in loss 
of visual function (Ambati and Fowler, 2012; Kurihara et al., 2016). Accumulating 
subretinal microglia and other mononuclear phagocytes can also directly instigate 
death of photoreceptors in the vicinity by engaging in indiscriminate phagocytosis 
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of stressed but living photoreceptors (Zhao et al., 2015a). Furthermore, the pro-
inflammatory milieu induced by reactive subretinal mononuclear phagocytes can 
also promote photoreceptor cell death (Scholz et al., 2015c). We have indeed 
demonstrated in our previous research that conditioned medium obtained from 
reactive human and murine microglial cells triggers photoreceptor apoptosis 
(Madeira et al., 2018; Wiedemann et al., 2018).  
The presence of reactive microglia in the outer retina is not a phenomenon unique 
to AMD but is also observed in other retinal degenerative pathologies such as 
Retinitis pigmentosa (RP) (Gupta et al., 2003). RP is the most prevalent and 
severe form of inherited retinopathies and is brought about by the primary 
degeneration of mutation containing rods and the subsequent degeneration of 
cones (Hartong et al., 2006). Microglia in human RP patients migrate to the 
photoreceptor layer following cues from apoptotic rods and engage in the 
phagocytic clearance of cellular corpses and debris (Gupta et al., 2003). Bloated 
microglia containing rhodopsin-positive cytoplasmic inclusions have indeed been 
demonstrated in the outer retina of RP patients using immunocytochemistry with 
microglia and rod cell-specific markers (Gupta et al., 2003). In addition to 
phagocytic clearance of degenerate cells, bloated infiltrating microglia secrete 
high levels of pro-inflammatory molecules such as TNF-α, IL-1β, CCL5 (alias 
RANTES) and CCL2 (alias MCP-1) that kill normal neurons and accentuate the 
ongoing degenerative process (Zeng et al., 2005). Intriguingly, using the retinal 
degeneration 10 (rd10) mouse model of RP, Guo et al. reported that mice 
deficient in ccr2 exhibited significantly reduced number of microglia infiltrating the 
photoreceptor layer compared to ccr2+/+ rd10 controls, indicating that the 
ccr2/ccl2 signaling pathway plays a key role in mobilizing microglia into the 
degenerating photoreceptor layer (Guo et al., 2012). Importantly, the reduced 
microglial infiltration observed in ccr2−/− rd10 mice was associated with increased 
retinal thickness and function, confirming microglia’s involvement in inducing 
degenerative changes during retinal pathology (Guo et al., 2012). 
In diabetic retinopathy (DR), which is the most common ocular complication of 
diabetes mellitus, hypertrophic and amoeboid microglia are present at different 
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stages of the disease and are mainly associated with retinal vasculature, cotton-
wool spots and microaneurysms in the inner retina (Grigsby et al., 2014; Zeng et 
al., 2000). In the non-proliferative form of the disease, there is a moderate 
increase in the number of reactive microglia which are mostly clustered around 
perivascular region involving arterioles, venules and capillaries as well as around 
fresh hemorrhages in microaneurysms (Zeng et al., 2008). In the intermediate 
pre-proliferative disease form, there is a dramatic increase in reactive microglia 
which cluster around peripheral regions of cotton-wool spots and dilated vessels 
(Zeng et al., 2008). Lastly, in the proliferative form of the disease characterized 
by pathological neovascularization, there is a marked increase in the number of 
reactive microglia in the GCL which heavily surround the new vessels in the nerve 
fibre layer and the optic nerve head where the proliferative process is most 
prominent (Zeng et al., 2008). This close topological association between 
reactive microglia and the perivascular compartments in human DR is postulated 
to exacerbate vascular permeability via pro-inflammatory mechanisms (Grigsby 
et al., 2014; Zeng et al., 2008).  
Similarly in the human glaucomatous eyes, clusters of large amoeboid microglia 
are found in the compressed prelaminar and lamina cribrosa regions where they 
surround blood vessels and form concentric rings (Neufeld, 1999). In addition, 
reactive microglia occurring either singly or in clusters are found in the 
parapapillary chorioretinal region (where the RPE and the bruch’s membrane 
terminate) of glaucomatous optic nerve heads (Neufeld, 1999). Of note is that 
microglia activation in the glaucomatous retina occurs prior to overt RGCs 
neurodegeneration, suggesting that microglial neuroinflammatory responses play 
a critical role in the onset and perpetuation of RGC loss (Bosco et al., 2011; Inman 
and Horner, 2007). (Bosco et al., 2011; Inman and Horner, 2007). The precise 
mechanisms involved in microglia mediated RGCs neurodegeneration remains 
poorly understood, but involves, at least in-part, the upregulation of Toll-like 
receptor (TLR) 4 and the secretion of high amounts of pro-inflammatory 
mediators TNF-α, IL-6 and nitric oxide (NO) (Echevarria et al., 2017; Neufeld et 
al., 1997; Sappington and Calkins, 2006; Tezel et al., 2004; Vidal et al., 2006). 
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Consistently, the depletion of TNF-R1 or IL-6 or the pharmacological inhibition of 
TLR4 or NO synthesis significantly abrogates the loss of RGCs associated with 
experimental animal models of glaucoma (Echevarria et al., 2017; Tezel et al., 
2004; Vidal et al., 2006).    
In summary, ample evidence generated from experimental animal models to 
human tissue shows unequivocally that microglia play a central role in the 
pathophysiology of retinal neurodegenerative disorders and thus cannot be 
simply regarded as “innocent” bystanders of disease. Moreover, microglia 
responsiveness to noxious stimuli during retinal pathology suggests that these 
cells have the potential to act as diagnostic biomarkers for predicting disease 
onset, disease exacerbation, as well as response to treatment (Karlstetter et al., 
2015). It is therefore imperative that we clearly understand the mechanisms 
underlying the establishment, maintenance and regulation of microglia responses 
during normal and pathological conditions. Such advances will provide an 
opportunity to better pinpoint candidate molecules and signal-transduction 
pathways that are dysregulated in overreactive neurotoxic microglia and set the 
stage for better-informed immunomodulatory strategies.  
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Figure 4: Schematic representation of microglia reactivity in the retina. Under 
steady state conditions, microglia reside in the plexiform layers where they contribute 
constitutively to maintaining neuronal synaptic structures, engage in phagocytosis of cell 
debris and constantly surveil their microenvironment for any disturbance in retinal 
homeostasis. When retinal neurons or the RPE suffer from noxious insults that lead to 
alteration in normal cellular function and/or degeneration, microglia become rapidly 
alerted, transform into amoeboid phagocytes and migrate to the lesion sites in an attempt 
to restore homeostasis. However, if the insults persist, such as in aging and degenerative 
diseases of the retina, microglia become pathologically activated and produce 
exaggerated levels of pro-inflammatory mediators that contribute to tissue damage and 
exacerbate disease severity. Figure adopted and modified from (Akhtar-Schäfer et al., 
2018).  
 
   
   
  Introduction 
 
21 
 
1.2.4 Transcriptional control of microglia phenotypes in health 
and disease 
Much of our understanding of cell-type specific transcriptional regulation has 
come from detailed analysis of promoter (regulatory) regions which harbor 
sequence elements that are targets for signal dependent regulation (Holtman et 
al., 2017). Promoters are primarily occupied by widely expressed transcription 
factors such as SP1 and GABP which by themselves are incapable of 
orchestrating cell-type specific gene expression (Holtman et al., 2017). To 
generate cell-type specific programs of gene expression, distant gene regulatory 
sequences known as enhancers are required (Holtman et al., 2017; Smale and 
Natoli, 2014). A classical feature of enhancers is the presence of heterotypic 
clusters of binding sites for one or more lineage determining transcription factors 
(LDTF) and for broadly expressed stimulus dependent transcription factors 
(SDTF) (Figure 5) (Ghisletti et al., 2010; Holtman et al., 2017). In myeloid derived 
cells, such LDTFs include PU box binding-1 (PU.1), Runt-related transcription 
factor 1 (RUNX1) and Interferon regulatory factor 8 (IRF8) (Kierdorf et al., 2013). 
These factors play fundamental roles in microgliogenesis (Ginhoux et al., 2010; 
Jin et al., 2012; Kierdorf and Prinz, 2013; Satoh et al., 2014). In addition, they 
have been shown to be constitutively bound to enhancers where they collaborate 
with other lineage determining factors to induce histone modifications associated 
with a primed state of activity (Smale and Natoli, 2014).  
In macrophages for instance, enhancers controlling endotoxin-stimulated gene 
expression are almost invariably bound by the lineage dependent Ets 
transcription factor Pu.1 (Ghisletti et al., 2010). Collaborative DNA binding of Pu.1 
with other partner TFs such as C/EBPβ leads to the deposition of monomethyl 
groups on lysine 4 of histone 3 (H3K4) and the displacement of nucleosomes to 
expose enhancer DNA sequences (Figure 5) (Ghisletti et al., 2010; Heinz et al., 
2010). Notably, the ectopic expression of Pu.1 in NIH-3T3 mouse fibroblast cells 
results in the depletion of nucleosomes in Pu.1 bound regions as well as several-
fold increase in the histone modification H3K4me1 in regions corresponding to 
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macrophage enhancers (Ghisletti et al., 2010). High levels of the histone mark 
H3K4me1 is a core chromatin signature of primed enhancers and serves as a 
beacon for signal-dependent effectors of signaling pathways such as nuclear 
factor-κB (NFκB), interferon responsive factors (IRFs) and activator protein 1 (AP-
1) (Ghisletti et al., 2010; Heinz et al., 2010; Smale and Natoli, 2014). The 
subsequent binding of SDTFs in the presence of stimulus promotes the 
recruitment of the ubiquitously expressed histone acetyltransferase (HAT) p300 
to the nucleosome depleted enhancer regions with concomitant increase in the 
acetylation states of various residues of histones H3 and H4 (Heintzman et al., 
2007; Smale and Natoli, 2014; Visel et al., 2009). Indeed, p300-mediated histone 
3 lysine 27 acetylation (H3K27Ac) has been reported to be a distinct epigenetic 
mark for active enhancers (Raisner et al., 2018). The observations that SDTFs 
bind to enhancer landscapes predetermined by LDTFs such as Pu.1 in the 
presence of stimulus partially explains how broadly expressed TFs can regulate 
tissue-resident macrophage-specific gene expression (Crotti and Ransohoff, 
2016; Holtman et al., 2017)  
 
Figure 5: Enhancer-promoter interactions drive cell specific gene expression. (A) 
Promoters are primarily occupied by broadly expressed transcription factors which by 
themselves are incapable of orchestrating cell-type specific gene expression. Enhancers 
occupied by LDTFs and SDTFs interact with promoters to achieve cell type-specific 
expression and response profiles. (B) Initial steps of enhancer selection in closed 
chromatin regions containing regularly positioned nucleosomes involves the binding of 
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LDTFs. This results in the depletion/sliding of nucleosomes to expose enhancer DNA 
sequences. LDTFs also deposit stereotypical histone marks such as H3K4me1 that act 
as beacons for SDTFs. The net effect of LDTFs binding is the maintenance of inducible 
genes in a silent, yet primed state which can be rapidly induced in the presence of stimuli. 
Figures A and B adopted from (Holtman et al., 2017).   
Several LDTFs have been shown to play roles in maintaining the unique resting 
but surveilling phenotype of microglia cells that is characteristic of a healthy CNS 
(Holtman et al., 2017). RUNX1, which is expressed as early as embryonic day 
6.5 in erythromyeloid precursors, has been shown to promote the transition of 
amoeboid microglia to the ramified deactivated state during brain development 
(Kierdorf et al., 2013; Zusso et al., 2012). Consistently, mouse primary microglia 
cells infected with GFP-expressing adenovirus was shown to express 
significantly high levels of the proinflammatory enzyme iNOS when compared 
with adenovirus infected primary cultures transduced with Runx1 (Zusso et al., 
2012). SALL1, a zinc finger transcriptional repressor whose expression in the 
CNS is virtually exclusive to adult microglia, is another factor involved in the 
maintenance of microglia homeostasis (Buttgereit et al., 2016). Ablation of Sall1 
results in the conversion of microglia from a ramified phenotype to reactive 
phenotype characterized by shorter, thicker processes and a larger cell soma 
(Buttgereit et al., 2016). In addition, Sall1 deletion in microglia induces alterations 
in neurogenesis that perturb CNS homeostasis (Buttgereit et al., 2016). Another 
important transcription factor expressed by microglia during their transition from 
pre-microglia to mature microglia is MAFB (Matcovitch-Natan et al., 2016). Loss 
of MafB expression in microglia leads to the disruption of developmental genes 
and the upregulation of interferon and inflammation-related pathways in adult 
mice (Matcovitch-Natan et al., 2016).  
In response to inflammatory stimuli, several SDTFs also play crucial roles in 
limiting microglia mediated inflammatory responses and inducing neuroprotective 
behavior. NR4A2 (Nuclear receptor subfamily 4, group A, member 2), also known 
as Nurr1, is an orphan nuclear receptor that is crucial for the development and 
homeostasis of dopaminergic neurons (Zetterström et al., 1997). NR4A2 has 
been shown to protect against loss of dopaminergic neurons by suppressing pro-
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inflammatory signaling in microglia and astrocytes (De Miranda et al., 2015; Saijo 
et al., 2009). The anti-inflammatory mechanism involves the recruitment of 
NR4A2 to NF-κB-p65 on inflammatory gene promoters and the subsequent 
recruitment of corepressor for repressor element 1 silencing transcription factor 
(CoREST) and the nuclear receptor corepressor 2 (NCOR2) (De Miranda et al., 
2015; Saijo et al., 2009). The recruitment of CoREST and NCOR2 to the 
inflammatory gene promoters results in the clearance of NF-κB-p65 and 
restoration of activated pro-inflammatory gene transcription to a basal state (De 
Miranda et al., 2015; Saijo et al., 2009).   
Ligation of estrogen receptors alpha and beta (ERα & ERβ) by endogenous and 
synthetic estrogen ligands has also been shown to exert potent 
immunomodulatory effects in reactive microglia (Arevalo et al., 2015; Bruce-
Keller et al., 2000; Saijo et al., 2011). 17β‑estradiol (estradiol), produced both in 
the CNS and in peripheral organs by aromatase-mediated conversion of 
testosterone, is the most potent estrogen and has been shown in a multitude of 
studies to attenuate microglia inflammatory responses through both ERα and 
ERβ activation (Bruce-Keller et al., 2000; Liu et al., 2005; Vegeto et al., 2003; 
Zhu et al., 2015). Similarly, Androstenediol, an ERβ subtype-specific ligand 
produced in the brain, has been shown to inhibit the magnitude and duration of 
microglia inflammatory responses by recruiting C-terminal binding protein (CtBP) 
corepressor complexes to AP-1 dependent promoters (Saijo et al., 2011). 
Interestingly, the genetic ablation of ERα leads to a spontaneous reactive 
phenotype of microglia in the brains of adult ERα-null mice, demonstrating a 
critical role for this receptor in the maintenance of microglia homeostasis (Vegeto 
et al., 2003).  
NF-E2-related factor-2 (NRF2) is an essential transcription factor for protection 
against oxidative/xenobiotic stress and inflammation (Kobayashi et al., 2016). 
NRF2 suppresses inflammation by the upregulation of a battery of antioxidant 
cytoprotective proteins including hemeoxygenase-1 (HO-1), NAD(P)H quinone 
oxidoreductase-1 (NQO1), thioredoxins (TRXs) and enzymes of glutathione 
metabolism (Kobayashi et al., 2016; Lastres-Becker et al., 2014; Li et al., 2004; 
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Yang et al., 2015). Notably, (Kobayashi et al., 2016) demonstrated that NRF2 can 
also directly repress inflammation by inhibiting the recruitment of RNA Pol-II to 
proinflammatory genes such as IL-6 and IL-1β. Besides inhibiting inflammation 
and boosting the cellular antioxidant capacity, NRF2 activators also been 
demonstrated to enhance microglia phagocytic capacity via upregulation of the 
scavenger receptor CD36, suggesting that this pathway might be important in 
shaping tissue-restorative responses to neurodegenerative conditions (Zhao et 
al., 2015b). Indeed, in Alzheimer’s animal models and patients, stressed neurons 
signal microglia via fractalkine to activate the NRF2 pathway and attenuate 
microgliosis (Lastres-Becker et al., 2014).      
A large number of SDTFs are similarly involved in mediating pro-inflammatory 
gene expression in microglia, indicating the complexity of the inflammatory 
response (Stetson and Medzhitov, 2006). Because of this large number, we focus 
herein on a few of the best characterized inducers of inflammatory signaling in 
microglia which include NF-κB, AP-1 and signal transducers and activators of 
transcription (STAT) family members (Holtman et al., 2017; Medzhitov and 
Horng, 2009). NF-κB, a family of rapidly inducible transcription factors, was 
discovered more than 31 years ago and named after the gene it affected and the 
cell type it was discovered in: nuclear factor binding near the kappa light-chain 
gene in B cells (Sen and Baltimore, 1986; Zhang et al., 2017). NF-κB family 
consists of five different members, p65 (RelA), RelB, c-Rel, p50/p105 (NF-κB1) 
and p52/p100 (NF-κB2) which assemble into several homodimers and 
heterodimers and regulate different sets of target genes (Liu et al., 2017b). 
Without stimulation, NF-κB proteins are normally sequestered in the cytoplasm 
by a dedicated set of inhibitory proteins comprising the inhibitor of κB (IκB) family 
proteins, IκBα, IκBβ, IκBε, BCL-3, IκBz, IκBNS and the C-terminal portions of the 
precursor proteins p105 (IκBγ) and p100 (IκBδ) (Hayden and Ghosh, 2008; 
Zhang et al., 2017). Upon stimulation, IκB subunits undergo phosphorylation by 
a multi-subunit IκB kinase (IKK) complex composed of two kinase subunits IKKα 
and IKKβ and a regulatory subunit NF-κB essential modulator (NEMO), resulting 
in the rapid translocation of NF-κB members into the nucleus to induce 
 
   
   
  Introduction 
 
26 
 
transcription of target genes (Liu et al., 2017b; Zhang et al., 2017). While 
activation of some NF-κB members such as c-Rel can induce the transcription of 
genes that confer neuroprotection, the activation of the p50/RelA induces the 
transcription of apoptotic and inflammatory genes that mediate 
neurodegenerative processes (Lanzillotta et al., 2015). In microglia, diverse 
stimuli such as LPS, TNF-α, α-synuclein, amyloid-β, ROS and saturated fatty 
acids have been shown to activate NF-κB signaling. An unbalanced activation of 
NF-κB in microglia drives the progression and deterioration of multiple 
neurodegenerative diseases including Alzheimer’s, Parkinson’s and Amyotrophic 
lateral sclerosis (ALS) (Frakes et al., 2014). This has been elegantly 
demonstrated in a previous study using SOD1-G93A mice model of ALS, where 
the selective inhibition of microglial NF-κB led to the rescue of motor neurons 
survival and the extension of lifespan by delaying disease progression by 47% 
(Frakes et al., 2014). Of note is that suppression of NF-κB signaling in astrocytes 
was insufficient to attenuate neuronal cell death nor alter survival in the ALS mice, 
clearly demonstrating that neurodegenerative processes are predominantly 
driven by NF-κB signaling in pathological activated microglia and infiltrating 
mononuclear phagocytes (Frakes et al., 2014).  
AP-1, a heterodimeric transcriptional regulator comprising various combinations 
of FOS, JUN, MAF, ATF, and CREB family proteins has been described to 
function both as an SDTF and a LDTF (Fontana et al., 2015; Holtman et al., 2017; 
Nomaru et al., 2014; Phanstiel et al., 2017). AP-1 cooperatively binds to DNA 
sequences together with PU.1 and C/EBP to establish functionally active 
enhancers that are capable of driving both cell-specific gene expression and 
signal-dependent responses in macrophages (Heinz et al., 2010; Madrigal and 
Alasoo, 2018). In addition, AP-1 has been shown to participate in the formation 
of DNA loops that brings enhancer regions located hundreds of thousands of 
base pairs away in contact with their target genes (Phanstiel et al., 2017). Indeed, 
during differentiation of human monocytes to macrophages, both newly formed 
and pre-existing chromatin loops that acquire enhancer activity were shown to be 
strongly enriched for AP-1 (Phanstiel et al., 2017). Such gained and activated 
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loops enriched for AP-1 form hubs that connect multiple distal enhancers to a 
single gene promoter to drive increased expression of macrophage-specific 
genes (Figure 6) (Phanstiel et al., 2017).    
 
Figure 6: Multi-loop activation hubs that form at key macrophage genes during 
differentiation are AP-1 enriched. PMA induced differentiation of human monocytes to 
macrophages leads to the formation of multi-loop activation hubs through both pre-
existing and newly acquired DNA loops. These activation hubs form at key macrophage 
regulatory genes and are enriched for AP-1. They connect multiple distal enhancers to 
a single gene promoter to induce increased transcription. Figure adopted from (Phanstiel 
et al., 2017).   
In addition to enhancer selection and chromatin looping, AP-1 subunits have 
been shown to be pivotal in mediating microglia inflammatory responses (Nomaru 
et al., 2014). Microglia in Fosb-null mice challenged with kainite show significant 
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reductions in CD68 immunoreactivity and express significantly reduced levels of 
IL-6, TNF-α as well as anaphylatoxin C5a receptors C5ar1 and C5ar2 when 
compared to their wild-type counterparts (Nomaru et al., 2014). Similarly, blocking 
c-Jun N-terminal kinase (JNK) signaling pathway and activation of AP-1 using the 
flavonoid luteolin markedly reduces LPS-induced production of the pro-
inflammatory cytokine IL-6 in microglia (Jang et al., 2008).  
Signal transducer and activator of transcription (STAT) protein family are also 
crucial mediators of microglia inflammatory responses (Chen et al., 2018; 
Przanowski et al., 2014; Qin et al., 2012). They are activated by a single tyrosine 
phosphorylation event by Janus kinases (JAKs; JAK1, JAK2, JAK3 and TYK2) 
which associate with type I and II cytokine receptors (O’Shea and Plenge, 2012; 
Yan et al., 2018). Phosphorylated STATs form stable homodimers or 
heterodimers with other STAT proteins before translocating into the nucleus to 
activate transcription of target genes (O’Shea and Plenge, 2012). Prolonged 
signalling by pro-inflammatory cytokines via the JAK-STAT pathway is inhibited 
in a classical negative feedback loop by suppressor of cytokine signaling (SOCS) 
proteins whose expression is also STAT regulated (Yoshimura et al., 2007). In 
microglia, the constitutive activation of Stat1 and Stat3 leads to the expression of 
the histone 3 lysine-27 (H3K27) demethylase JMJD3, which, together with Stat1 
and Stat3, drives the expression of numerous pro-inflammatory cytokines and 
chemokines (Przanowski et al., 2014). Similarly, in experimental autoimmune 
encephalomyelitis (EAE) mice, myeloid specific ablation of SOCS3 leads to a 
heightened activation of the STAT3 and induces a more severe form of EAE 
characterized by enhanced expression of pro-inflammatory mediators and 
extensive demyelination in the cerebellum compared to the wildtype controls (Qin 
et al., 2012). In corroboration, experimental autoimmune uveoretinitis (EAU) mice 
lacking SOCS3 in myeloid cells display an exaggerated retinal inflammatory 
response characterized by excessive IL-1β, TNF-α and IFN-γ production (Chen 
et al., 2018). In contrast, inhibition of JAK/STAT1 signaling via the overexpression 
of SOCS1 in EAU mice lessens disease severity by inhibiting inflammatory 
chemokine expression and suppressing the recruitment and infiltration of 
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inflammatory cells into the retina (Yu et al., 2011). Taken together, this evidence 
suggests that uncontrolled STAT1/STAT3 activity promotes microglia activation 
and CNS inflammation. 
Many factors involved in the transcriptional control of microglia phenotypes in 
health and disease have been identified; however, there are many more that 
remain unknown. Alterations in microglia functionality are involved in the 
pathogenesis of many neurodegenerative diseases (Crotti and Ransohoff, 2016), 
and therefore a major aim for future research will be to identify specific factors 
responsible for inhibiting the expression of genes that maintain microglia 
physiology or overexpressing disease specific genes such as the mitochondrial 
translocator protein (18 kDa; TSPO) (Karlstetter et al., 2014b; Wang et al., 2014).     
1.3 Translocator protein (18 kDa) (TSPO) 
The translocator protein (18kDa) (TSPO) was discovered in 1977 as a high 
affinity benzodiazepine binding site in peripheral tissues that was distinct from the 
central benzodiazepine receptor, hence the previous denomination peripheral 
benzodiazepine receptor (PBR) (Braestrup et al., 1977). It is a 5α-helical 
transmembrane protein that is highly conserved throughout evolution (Figure 7) 
(Rupprecht et al., 2010). The human TSPO amino acid sequence shares 
approximately 33.5%, 42.6% and 81.1% identity with the sequence from 
Rhodobacter sphaeroides, Drosophila melanogaster and Mus musculus 
respectively (Selvaraj and Stocco, 2015). TSPO homologs, which are not only 
found in the animal kingdom but also in plants such as Arabidopsis thaliana 
(Balsemão-Pires et al., 2011), show a high degree of functional conservation 
(Notter et al., 2018; Yeliseev et al., 1997). For instance, when rat Tspo is 
expressed in TspO− strain of the proteobacterium Rhodobacter sphaeroides, it is 
able to fully rescue the phenotypic changes induced by TspO deletion (Yeliseev 
et al., 1997).     
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Figure 7: TSPO gene is highly conserved throughout evolution. Analysis of exons 
2-4 of the TSPO gene using the Evolutionary Conserved Regions Browser (Ovcharenko 
et al., 2004) (http://ecrbrowser.dcode.org/)  demonstrates sequence conservation 
between chicken, frog, opossum, rat, mouse, dog and rhesus monkey. Base genome is 
from human. Exons are presented in blue, untranslated regions (UTRs) in yellow, introns 
in salmon, simple repeats and transposable elements in green and intergenic sequences 
in red. Annotated genes are depicted as horizontal blue lines above and below the graph, 
with strand/transcriptional orientation indicated by arrows.    
The TSPO gene consists of four exons, with exon 1 and half of exon 4 remaining 
untranslated (Lin et al., 1993). The encoded protein is localized primarily to the 
outer mitochondrial membrane, where it interacts with both outer and inner 
mitochondrial membrane proteins such as the voltage-dependent anion channel 
(VDAC) and the adenine nucleotide transporter (ANT) to form a mitochondrial 
multiprotein complex (McEnery et al., 1992; Veenman et al., 2008). TSPO 2, a 
less characterized paralogous protein to TSPO, is expressed in developing 
erythrocytes and is localized to the endoplasmic reticulum and nuclear 
membranes (Selvaraj and Stocco, 2015). TSPO displays a high constitutive 
expression in steroidogenic tissues such as adrenal glands, gonads, white and 
brown adipose tissue, lungs and the placenta, but is very weakly expressed in 
the healthy brain (Karlstetter et al., 2014; Selvaraj and Stocco, 2015). However, 
during diverse neuropathological conditions in the brain, there is a dramatic 
increase in TSPO expression that colocalizes predominantly with activated 
microglia (Beckers et al., 2018; Daugherty et al., 2013). This robust increase in 
 
   
   
  Introduction 
 
31 
 
microglial TSPO expression from near absence has led to the development of 
numerous TSPO positron-emission tomography (PET) ligands for the non-
invasive imaging of neuroinflammation (Banati et al., 2014; Liu et al., 2014). 
Similarly during retinal pathology, there is a strong induction in microglial TSPO 
expression which accurately marks the duration and extent of neuroinflammatory 
responses in the retina (Karlstetter et al., 2014a; Wang et al., 2014).   
The most studied physiological function of TSPO involves the transport of 
cholesterol from the outer to the inner mitochondrial membrane as a rate limiting 
step in steroid formation (Midzak et al., 2015). Evidence that linked TSPO 
function to steroidogenesis came from earlier studies which showed that TSPO 
binding chemicals like PK11195 could enhance steroid hormone production in Y-
1 adrenal tumor cells and that steroidogenesis was significantly hampered in 
Tspo-negative leydig cells compared to normal cells (Mukhin et al., 1989; 
Papadopoulos et al., 1997; Selvaraj and Stocco, 2015). Further evidence in 
support of the steroidogenic role showed that TSPO could strongly bind 
cholesterol molecules via a cholesterol recognition amino acid consensus 
(CRAC) motif located at the C-terminus of the protein (Li and Papadopoulos, 
1998; Selvaraj and Stocco, 2015). However, recent works from independent 
research groups have strongly refuted TSPO’s involvement in steroidogenesis 
(Banati et al., 2014; Morohaku et al., 2014; Tu et al., 2014). Findings from these 
studies showed that steroid hormone production remained unaltered following 
cell specific or global TSPO knockout in mice and fruit flies (Banati et al., 2014; 
Morohaku et al., 2014; Tu et al., 2014). In addition, using CRISPR/Cas9 genome 
editing system to generate Tspo−/− leydig cells, Tu et al. demonstrated that the 
pharmacological effect of PK11195 on steroidogenesis is not mediated through 
TSPO but rather represent off-target effects (Notter et al., 2018; Tu et al., 2015). 
However, while these results raise valid concerns, further studies are necessary 
before TSPO’s involvement in steroidogenesis can be invalidated. This is 
especially so, since recent studies using the most sensitive high-performance 
liquid chromatography/mass spectrometry technique (HPLC/MS) to evaluate 
steroid levels support the importance of TSPO as a steroidogenesis regulator 
particularly under hormonal stimulation and during aging (Barron et al., 2018; 
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Owen et al., 2017). Of note, Tspo mutant rats showed increased neutral lipid 
accumulation in the adrenal glands and testis, reduced circulating testosterone 
and undetectable levels of the neurosteroid allopregnanolone (Owen et al., 
2017).  
Previous studies using pharmacological ligands or genetic loss of function have 
also implicated TSPO in cellular bioenergetics (Banati et al., 2014; Liu et al., 
2017a). A high-throughput small molecule screen in zebrafish demonstrated that 
the TSPO ligands PK11195 and Ro5-4864 affect glucose homeostasis and 
mitochondrial energy production (Gut et al., 2013). Consistently, over-expression 
of Tspo in Jurkat cells with barely detectable endogenous expression resulted in 
the upregulation of genes involved in mitochondrial respiration with concomitant 
increase in mitochondrial ATP production (Liu et al., 2017a). Additionally, it is 
worth noting that in the retina, TSPO is constitutively expressed in RPE cells 
which require an active metabolism to maintain outer retina homeostasis, but its 
expression is robustly induced in microglia only during times of high energy 
demands to support inflammatory responses (Figure 8) (Orihuela et al., 2016; 
Scholz et al., 2015b). Moreover, microglia derived from Tspo−/− mice show an 
altered oxygen consumption rate and significantly reduced ATP production 
compared to wildtype controls (Banati et al., 2014). However, before TSPO can 
be conclusively termed as a regulator of mitochondrial energy metabolism, further 
experiments are needed to determine its precise contribution to this biological 
process.  
 
Figure 8: Constitutive and inducible Tspo expression in RPE and microglia cells. 
Photomicrographs of retina cross-sections from a healthy (A) and a light exposed mouse 
(B) stained with anti-TSPO antibody. (A) Constitutive expression of Tspo in the retina 
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pigment epithelium layer (RPE) of the healthy retina. Tspo staining almost non-existent 
in the plexiform layers where microglia reside. (B) Strong upregulation of Tspo 
expression in reactive amoeboid microglia (white arrow heads) present in the subretinal 
space of the degenerating retina. Figure (A) provided by Katrin Klee, Department of 
Ophthalmology, University of Zurich, Switzerland. Figure (B) provided by Dr. Rebecca 
Scholz, alumni of the Retinal immunology laboratory, University Hospital of Cologne, 
Germany.    
Other cellular processes where TSPO has been implicated include regulation of 
the mitochondrial membrane permeability transition pore (MPTP) (Elkamhawy et 
al., 2017), production of reactive oxygen species (ROS) (Gatliff et al., 2014), 
cellular proliferation (Rechichi et al., 2008), apoptosis (Veenman and Gavish, 
2012), mitochondrial calcium homeostasis (Gatliff et al., 2017), tetrapyrrole 
biosynthesis (Batoko et al., 2015b, 2015a) and immune modulatory effects 
(Daugherty et al., 2013; Karlstetter et al., 2014a; Scholz et al., 2015b; Wang et 
al., 2014).  
1.4 Immunomodulatory and neuroprotective effects of TSPO 
ligands 
TSPO is a sensitive biomarker of neuroinflammation and is upregulated in a 
variety of CNS diseases including multiple sclerosis (MS) (Daugherty et al., 
2013), Alzheimer's (Edison et al., 2008), Parkinson's (Ouchi et al., 2005), 
Huntington's (Messmer and Reynolds, 1998), amyotrophic lateral sclerosis 
(Turner et al., 2004) and ischemic stroke (Cosenza-Nashat et al., 2009). Although 
TSPO ligands have been used mostly for non-invasive diagnostic imaging of the 
affected brain in disease, some studies have also demonstrated their ability to 
mitigate neuroinflammatory responses and offer neuroprotection (Daugherty et 
al., 2013). In an experimental autoimmune encephalomyelitis (EAE) mouse 
model for MS, treatment with the TSPO ligand etifoxine attenuated EAE severity 
through the reduction of pro-inflammatory cytokine expression (IL-1β, IL-17 and 
IFN-γ) and peripheral immune cell infiltration in the spinal cord (Daugherty et al., 
2013). Moreover, treatment with etifoxine was associated with increased 
oligodendroglial regeneration following inflammatory demyelination in EAE 
(Daugherty et al., 2013). In a collagenase mouse model of intracerebral 
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hemorrhage (ICH), treatment with etifoxine was associated with reduced 
leukocyte infiltration into the brain, improved BBB integrity and the inhibition of 
cellular apoptosis and microglia-mediated pro-inflammatory responses (Li et al., 
2017). Notably, depletion of microglia using a colony-stimulating factor 1 receptor 
inhibitor abolished the protective effects of etifoxine, demonstrating that the 
therapeutic effects of etifoxine require microglia (Li et al., 2017).  
Similarly during retinal pathology, we and others have demonstrated that 
endogenous and synthetic TSPO ligands effectively counter-regulate microgliosis 
and exert potent neuroprotective effects (Karlstetter et al., 2014b; Wang et al., 
2014). Using an endotoxin model of retinal inflammation, Wang et al. 
demonstrated that as reactive retinal microglia upregulate Tspo expression, 
astrocytes and Müller cells simultaneously upregulate the production and 
secretion of a 9kDa endogenous TSPO protein ligand, namely diazepine binding 
inhibitor protein (DBI) (Wang et al., 2014). Secreted DBI is taken up by the retinal 
microglia, and the interaction between DBI and TSPO serves to limit the 
magnitude of microglial inflammatory responses and facilitate a return to baseline 
quiescence (Figure 9) (Wang et al., 2014). Exploiting this endogenous 
immunomodulatory mechanism, we investigated the ability of a synthetic and 
highly specific TSPO binding chemical, XBD173 (AC-5216, emapunil), to dampen 
microglial reactivity in the light-induced retinal degeneration mouse model 
(Scholz et al., 2015b). Findings from this study revealed that XBD173 strongly 
inhibited the accumulation of reactive microglia in the outer retina with 
concomitant preservation of the photoreceptor layer (Scholz et al., 2015b). 
Moreover, treatment with XBD173 significantly suppressed the expression of pro-
inflammatory genes and the morphological transition of microglia towards an 
amoeboid phenotype in the light-damaged retina (Scholz et al., 2015b). Taken 
together, these findings highlight the immunomodulatory and neuroprotective 
properties of TSPO ligands and underscore their potential as pharmacological 
therapies in the treatment of neurodegenerative disorders.  
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Figure 9: Immunomodulatory effects of endogenous and synthetic TSPO ligands. 
Specific cues emanating from dying photoreceptors strongly induce TSPO expression in 
microglia cells. Simultaneously, dying photoreceptors signal Müller cells to upregulate 
the expression and secretion of the endogenous TSPO ligand Diazepine binding inhibitor 
(DBI) protein. Secreted DBI and its biologically active cleavage product 
triakontatetraneuropeptide (TTN) are subsequently taken up by microglia cells. The 
binding of DBI, TTN or the synthetic ligand XBD173 limits the magnitude and duration of 
microglia inflammatory responses and promotes their return to baseline quiescence. 
Figure adopted and modified from (Rashid et al., 2018c).  
1.5 Hypothesis and Specific Aims of the Thesis 
Neuroinflammation is a key hallmark of neurodegenerative diseases and other 
CNS pathologies. Microglia, the guard cells of the CNS, play a critical role in 
orchestrating such neuroinflammatory reactions in response to noxious stimuli. 
While acute neuroinflammatory responses are beneficial and promote tissue 
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repair and remodeling, chronic neuroinflammation results in tissue degeneration 
and exacerbation of disease severity. Therefore, pharmacological approaches 
that synchronously inhibit dysregulated microglial inflammatory responses while 
enhancing their beneficial neuroprotective functions presents as promising 
therapeutic tools for the management and prevention of neurodegenerative 
diseases. Mitochondrial Translocator Protein (18kDa; TSPO) is lowly expressed 
in quiescent microglia in the healthy CNS but robustly upregulated in response to 
injury and neuroinflammation. Importantly, we and others have previously shown 
that TSPO serves as an attractive therapeutic target for alleviation of immoderate 
microglia-mediated neuroinflammatory responses during degenerative disorders 
of the CNS including the retina. However, understanding the molecular 
mechanisms involved in the aberrant expression of TSPO in microglia during 
disease is paramount prior to the utilization of this protein as a drug target for 
interventions aimed at limiting excessive CNS inflammation. Therefore, the main 
objective of this study was to investigate how TSPO transcriptional regulation is 
achieved in microglial cells. Given the distinctly different expression in microglia, 
we hypothesized that the transcriptional regulation of TSPO was achieved, at 
least in part, via microglia specific factors. To test this hypothesis, functional 
characterization of the Tspo promoter was carried out in a mouse BV-2 microglial 
cell line and the minimal sequence necessary to support basal and 
lipopolysaccharide (LPS) induced promoter activity determined. In addition, the 
transcriptional regulation of Tspo in BV-2 microglia was compared and contrasted 
with that of myeloid derived RAW 264.7 macrophage cell line and the retinal 
pigment epithelial cell line ARPE-19.  
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2.0 Materials and Methods 
2.1 Materials 
2.1.1 Mammalian and bacteria cells 
Table 1: List of all cell lines and bacteria strain used in the study 
Cell lines  Origin 
BV-2 murine microglia cell-line Murine  primary microglial  cultures  
isolated from 1-week- old C57BL/6 mice 
and infected with a v-raf/v-myc 
recombinant retrovirus (Blasi et al., 1990) 
ARPE-19 human retinal pigment epithelial 
cell-line 
A spontaneously arising retinal pigment 
epithelial (RPE) cell line derived in 1986 
from the normal eyes of a 19-year-old 
male donor (Dunn et al., 1996)     
RAW-264.7 macrophage cell-line Cell-line isolated mice tumors induced with 
Abelson leukemia virus (A-MuLV). 
(Raschke et al., 1978)  
Bacteria Strain  Origin 
DH5α  Escherichia Coli (E. Coli) 
2.1.2 Culture media 
Table 2: Reagents and recipes for cell culture and LB media/plates 
Reagents Manufacturer, Cat. No. 
Dulbecco's Modified Eagle Medium (DMEM)  Sigma-Aldrich, #D6429 
DMEM/F-12  Gibco, # 11554546 
Roswell Park Memorial Institute (RPMI) 
1640 medium 
Gibco, # 21875034 
Dulbecco's Phosphate-Buffered Saline 
(DPBS)  
Gibco, #14190 
β-mercaptoethanol  Sigma-Aldrich, #M-7154 
Fetal Calf Serum (FCS)  Gibco, #10270-106 
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L-Glutamine (200mM) Gibco, #25030081  
Trypsin/EDTA  Sigma-Aldrich, #T3924 
Agar-Agar Merck, #101614 
Ampicillin sodium salt Roth, #K029.2 
Chloramphenicol Calbiochem, #220551 
Sodium chloride (NaCl) Merck, #106400 
Pepton from casein Roth, #8986 
Yeast extract  AppliChem, #A1552 
Cell culture media  Ingredients 
BV-2 cell-line  RPMI 1640 medium 
5 % FCS 
1 % L-Glutamine 
195 nM β-mercaptoethanol 
1 % Penicillin/Streptomycin 
RAW 264.7 cell-line DMEM medium 
10 % FCS 
1 % Penicillin/Streptomycin 
ARPE-19 cell-line DMEM/ F-12 medium 
10 % FCS 
1 % Penicillin/Streptomycin 
Lysogeny broth (LB) media Recipe 
LB-media 10 g/l Yeast extract 
20 g/l NaCl 
20 g/l Peptone 
LB ampicillin media (LB-amp)  
LB-amp agar plates  
100 μg/ml ampicillin in LB-media 
14 g/l agar-agar in LB-amp 
LB chloramphenicol media  
LB chloramphenicol agar plates  
20 μg/ml chloramphenicol in LB-media 
14 g/l agar-agar in LB chloramphenicol 
 
2.1.3 Enzymes 
Table 3: List of all enzymes and their corresponding buffers used in the 
study 
Enzyme Manufacturer, Article number 
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PfuUltra II fusion HS DNA polymerase Agilent Technologies, 600670 
10x PfuUltra II Reaction Buffer Supplied with the enzyme 
RevertAid H Minus Reverse 
Transcriptase 
ThermoFisher Scientific, Kit #K1622  
5x Reaction Buffer ThermoFisher Scientific, Kit #K1622 
Taq Polymerase (PCR)  Genaxxon, M3001 
10x Reaction Buffer Genaxxon, M3454 
FastDigest KpnI ThermoFisher Scientific, FD0524   
FastDigest HindIII ThermoFisher Scientific, FD0504  
10x Fast Digest Buffer Supplied with the enzymes 
10x Fast Digest Green Buffer Supplied with the enzymes 
T4 DNA Ligase New England Biolabs, M0202S 
10x T4 DNA ligase reaction buffer Supplied with the enzyme 
Proteinase K Merck Chemicals GmbH, 20-298 
 
2.1.4 Antibodies 
Table 4: List of all antibodies used in the study 
Antibody Manufacturer, Article number 
Anti-SP1 antibody ChIP Grade Abcam, ab13370 
Anti-c-Jun antibody ChIP Grade Abcam, ab31419 
Anti-PBR antibody [EPR5384]  Abcam, ab109497 
Sp3 Antibody (D-20) X Santa Cruz Biotechnology, sc-644 X 
Sp4 Antibody (V-20) X Santa Cruz Biotechnology, sc-645 X 
PU.1 Antibody (T-21) X Santa Cruz Biotechnology, sc-352 X 
c-Fos Antibody (4) X Santa Cruz Biotechnology, sc-52 X 
Stat3 Antibody (H-190) X Santa Cruz Biotechnology, sc-7179 X 
GAPDH Antibody (I-19)  Santa Cruz Biotechnology, sc-48166 
Actin Antibody (I-19) Santa Cruz Biotechnology, sc-1616 
IgG-HRP (donkey anti-goat) Santa Cruz Biotechnology, sc-2020 
IgG-HRP (goat anti-rabbit)  Agilent Dako, P0448 
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2.1.5 Buffers and solutions 
Table 5: Recipes for buffers and solutions used in this study 
Buffer/Solution Ingredients 
Manufacturer, Cat. 
No. 
1x PBS, pH 7.4 137 mM NaCl 
2.7 mM Potassium chloride (KCl)  
10 mM Disodium phosphate (Na2HPO4)  
1.8 mM Monopotassium phosphate 
(KH2PO4) 
Amresco, #E404 
1 tablet/100 ml dH2O 
6x Loading dye 60 % v/v Glycerine 
20 mM EDTA 
0.25 % w/v Bromophenol blue  
Roth, #3783.1 
listed above 
Sigma-Aldrich, #B-
6131 
1x TBE 1 M Tris, pH 7.5 
1 M Boric Acid 
20 mM EDTA 
Roth, #4855.3 
Sigma-Aldrich, #B6768 
Merck, #108421 
1x TBS-T 150 mM NaCl 
200 mM Tris 
0.1 % v/v Tween-20 
Merck, #106400 
listed above 
Merck, #822184 
Complete 
fixation solution 
90 µl of ChIP-IT® fixation buffer  
375 µl of 37% formaldehyde 
785 µl of nuclease free water 
Active Motif, #53038  
Sigma-Aldrich, 
#252549 
Antibody 
solution 
5 % w/v Non-fat Milk powder in TBS-T 
0.1% Tween-20 (TBS-T) in TBS-T 
Roth, #T145.3 
listed above 
RIPA buffer 50 mM Tris-HCl pH 7.4 
150 mM NaCl 
1 % v/v NP-40 
0.5 % w/v Sodium deoxycholate 
0.1 % w/v Sodium dodecyl sulfate (SDS) 
2 mM Phenylmethanesulfonylfluoride 
fluoride (PMSF) 
cOmplete™ mini protease inhibitor 
listed above 
listed above 
Calbiochem, #492016 
Sigma-Aldrich, #D6750 
Serva, #20765.03 
AppliChem, #A0999 
 
Roche, #11836153001 
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Running buffer 
  
  
192 mM Glycine 
250 mM Tris 
0.1 % w/v SDS 
AppliChem, #1067 
listed above 
listed above 
Transfer buffer 
  
  
192 mM Glycine 
250 mM Tris 
20 % v/v Methanol 
listed above 
listed above 
Chemsolute, 
#1437.2511 
Stripping buffer 
  
  
192 mM Glycine, pH 2.2 
0.0001 % w/v SDS 
0.01 % v/v Tween-20 
listed above 
listed above 
listed above 
2.1.6 Agarose and SDS-PAGE gels 
Table 6: Recipes for agarose and SDS-PAGE gels 
Gels  Ingredients Manufacturer, Cat. No. 
Agarose gel (1 & 2%) 
  
1-2 % w/v Agarose 
0.5 µg/ml Ethidium bromide in TBE 
Biozyme, #840004 
Sigma-Aldrich, #46067 
Running gel (15%) 15% Acrylamide v/v  
0.4 M Tris pH 8.8 
0.1 % w/v SDS 
0.1 % w/v Ammonium persulfate 
(APS) 
0.01 % v/v TEMED 
Roth, #A124.1 
listed above 
listed above 
Sigma-Aldrich, #A3678 
 
Roth, #2367.1 
Stacking gel 5 % v/v Acrylamide 
0.125 M Tris pH 6.8 
0.1 % w/v SDS 
0.1 % w/v APS 
10µl 0.005 % v/v TEMED       
listed above 
 
 
2.1.7 Kits 
Table 7: Commercially available kits used in this study 
Kit Manufacturer, Cat. No. 
LightCycler® 480 Probes Master Roche Applied Science, #04707494001 
NucleoSpin® Plasmid  Macherey-Nagel, #740588 
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NucleoBond® Xtra Midi Macherey-Nagel, #740410.100 
NucleoBond® Xtra Midi EF Macherey-Nagel, #740420.50 
NucleoSpin® RNA  Macherey-Nagel, #740955  
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel, #740609 
ONE-Glo™ Luciferase Assay System Promega, #E6110 
Pierce™ BCA Protein Assay Kit ThermoFisher Scientific, #23225 
Pierce™ ECL Western Blotting Substrate ThermoFisher Scientific, #32109 
SignalFire™ Elite ECL Reagent Cell Signaling Technology, #12757 
Q5® site-directed mutagenesis kit New England Biolabs, #E0554S 
Magna ChIP™ G -ChIP Kit Merck, #17-611  
2.1.8 Chemicals and reagents 
Table 8: List of chemicals and reagents used in this study 
Chemicals and reagents Manufacturer, Cat. No. 
2-Nitrophenyl b-D-galactopyranoside Carbosynth, #EN06363 
5X siRNA Buffer  Dharmacon, #B-002000-UB-100 
Dimethylsufoxid (DMSO) Serva, #20385.01 
dNTP-Set Genaxxon, #M3015 
Ethanol  Applichem, #A3678 
Ethanol 70% Applichem, #A2192 
Hydrochloric acid (HCL) 37% Roth, #X942 
Isopropanol Merck, #100995 
Laemmli sample buffer  Bio-Rad, #161-0747 
Lipofectamine™ 3000 Transfection Reagent ThermoFisher Scientific, L3000015 
LPS from E. coli :B4 Sigma-Aldrich, #L4391 
Magnesium chloride (2M solution in H2O) Sigma-Aldrich, #68475 
MassRuler DNA Ladder ThermoFisher Scientific, #SM0403 
PageRuler™ Prestained Protein Ladder ThermoFisher Scientific, #26616 
RNase away Molecular Biopro., #70003 
Sodium carbonate Roth, #P028.1 
TransIt-LT1 Transfection reagent Mirus, #MIR 2305 
Trichostatin A Sigma-Aldrich, #T8552  
Trypan blue Biochrom AG, #L6323 
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2.1.9 Devices 
Table 9: List of devices used in the study 
Device Manufacturer  
7900 HT Fast Real-Time PCR System  AB Applied Biosystems 
Adventurer Pro balance Ohaus® 
Bacterial incubator VWR International 
BlueMarine™ 200 Electrophoresis unit SERVA Electrophoresis GmbH 
Centrifuge 5415 R  Eppendorf 
Centrifuge Mini Star  VWR International 
DynaMag™-2 magnet ThermoFisher Scientific 
Explorer R Ex 124 balance  Ohaus® 
Galaxy 170S CO2 incubator Eppendorf / New Brunswick Scientific 
Heraeus Labofuge 400 R  Thermo Scientific 
Infinite®F200 Pro plate reader Tecan 
Intas Gel iX20 Imager  Intas 
LightCycler® 480 Instrument II  Roche Applied Science 
Matrix™ Multichannel Pipettes ThermoFisher Scientific 
Mini-Protean® Tetra System Bio-Rad 
MiniTrans-Blot® Cell Module Bio-Rad 
MSC-Advantage hood  Thermo Scientific 
MultiImageII Alpha Innotech 
NanoDrop 2000 Spectrophotometer  Thermo Scientific 
Neubauer counting chamber  OptikLabor 
Orbital incubator S1500 Stuart® 
PCR workstation VWR International 
peQSTAR 2x cycler  peQlab 
See-saw rocker SSL4  Stuart® 
Thermomixer compact Eppendorf 
TW20 watherbath Julabo 
Vibracell 75115 Sonicator  Fisher Bioblock Scientific 
Vortex-genie® Scientific IndustriesTM 
VWR Electrophoresis Power Source 250V VWR International 
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2.1.10 Software 
Table 10: List of software used in the study 
Software Manufacturer 
A plasmid Editor (ApE) M. Wayne Davis, University of Utah 
AlphaView FluorChem FC2 Cell Biosciences 
CSl Adobe Creative Suite Adobe Systems 
GraphPad Prism version 6.07 GraphPad Software, Inc. 
ImageJ 1.51j8 National Institutes of Health 
Intas Gel Documentation 3.39 software IntasScience Imaging 
LightCycler® 480 software 1.5.1  Roche Applied Science 
SDS 2.3 Applied Biosystems SDS 2.3 Applied Biosystems 
MatInspector software Genomatix Software, Inc. 
Mendeley version 1.19.2 Elsevier 
Microsoft office 365 pro plus Microsoft Corporation 
Nanodrop 2000/2000c software ThermoFisher Scientific 
2.2 Methods 
2.2.1 Cell culture 
Cell lines used in this study included murine BV-2 microglia and Raw-264.7 
macrophages and human ARPE-19 cells. Culture medium used to grow and 
maintain the cells is detailed in Table 1. For routine maintenance, cultures were 
grown in T75 flasks and maintained at 37°C in a humidified atmosphere of 5% 
CO2. At 80-90% confluence, BV-2 and Raw-264.7 cells were rinsed gently with 1x 
PBS and detached from the flasks by gentle scraping in 5 mls of warmed fresh 
medium. ARPE-19 cells were grown to confluency and detached by incubation 
with 5 mL trypsin at 37°C, 5% CO2 for 5 mins. Trypsin reaction was stopped by 
adding complete growth medium and the cell suspension transferred to a 50 ml 
falcon tube. Centrifugation was then done at 800 x g for 10 mins to separate the 
cells from the trypsin containing medium. All cells were split by a 1:5 dilution factor 
and appropriate volume resuspended in 10 mls of warmed medium. Cells were 
kept in culture until passage 20. 
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2.2.2 Plasmid construction 
Mouse BAC clone RP23-352L10 (RPCI) (Source BioScience, Nottingham, United 
Kingdom; GenBank accession number 712558) was used as template in a PCR 
reaction to amplify a 2.812 kb Tspo promoter sequence using modified primers 
containing KpnI and Hind-III restriction sites in the forward and reverse primers 
respectively. The PCR reactions were set-up as described in table 11 and run 
using the temperature profile outlined in table 12   
 
Table 11: PCR recipe to amplify Tspo promoter from mouse BAC clone 
Reaction component Amount 
Template DNA 100 ng  
Forward primer 1 µl (200 nM) 
Reverse primer 1 µl (200 nM) 
deoxynucleotide (dNTP) solution mix  1 µl (800 µM of total dNTP) 
PfuUltra II fusion HS DNA polymerase 0.5 µl  
PfuUltra II 10x PCR buffer 5 µl (final 1x MgCl2 concentration of 2 mM) 
Nuclease free dH2O Up to 50 μl 
 
Table 12: PCR temperature profile 
Step Temperature Time 
Initial Denaturation 95°C 5 mins 
 
35 cycles 
95 °C 
50°C  
72 °C 
40 seconds 
44 seconds 
80 seconds 
Final Extension 72 °C 10 mins  
Hold  8 °C  
 
The PCR reactions were carried out in triplicate, and 10 µl of each PCR reaction 
was mixed with 2 µl of 6x loading dye and analyzed on a 1% agarose gel. The 
remaining 40 µl of the PCR product from the 3 reactions was pooled together and 
cleaned using the NucleoSpin Gel and PCR clean-up kit. The purified PCR product 
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was then cut using high fidelity fast digest restriction enzymes as detailed in Table 
13 below. 
Table 13: Restriction digest protocol 
Reaction component Amount 
Purified PCR product 30 µl (~ 1.5 µg) 
10x Fast digest buffer 5 µl  
KpnI 5 µl 
Hind-III 5 µl 
Nuclease free dH2O Up to 50 μl 
 
Fifteen micrograms of the promoterless pGL4.10 firefly luciferase vector was also 
subjected to a double restriction digest using the same protocol outlined in Table 
12. The restriction digest products were then separated on a 1 % agarose gel 
before being excised out with clean scalpel and purified. The digested Tspo 
promoter fragment was then ligated into the promoterless pGL4.10 firefly 
luciferase reporter vector to generate plasmid pGL4.10-2733/+79. The recipe used 
to set up the ligation reaction is summarized in Table 14 below.  
Table 14: Ligation protocol 
Reaction component Amount 
Reporter vector (pGL4.10) DNA  2 µl (~ 200 ng) 
Insert (Tspo promoter sequence) DNA  14.5 µl (~ 320 ng) 
T4 DNA ligase 1.5 µl 
10x T4 DNA ligase reaction buffer 2 µl 
 
The ligated plasmid was transformed into E. coli bacterial strain DH5-α. Single 
colonies of the transformed bacteria were selected and transferred to 5 mls of LB 
broth containing 100 µg/ml ampicillin and grown overnight at 37 °C with vigorous 
shaking (170 rpm). Plasmid DNA was extracted from the bacterial culture using 
the NucleoSpin® Plasmid kit and tested for the presence of the insert by a double-
digest with restriction enzymes used earlier in the cloning steps (Table 15). Correct 
promoter sequences and orientation was verified by sanger sequencing using 
primers listed in Table 17. Plasmids pGL4.10-1915/+79, -1455/+79, -845/+79, -
791/+79, -733/+79, -680/+79, -593/+79, -520/+79, -168/+79, -143/+79, -125/+79 
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and pGL4.10-39/+79, carrying progressive unidirectional 5′ → 3′ deletions on the 
promoter were then generated by PCR using plasmid pGL4.10-2733/+79 as 
template and primers listed in Table 16.  
Table 15: Test digest protocol 
Reaction component Amount 
Plasmid DNA 11 µl  
10x Fast digest buffer 5 µl  
KpnI 0.5 µl 
Hind-III 0.5 µl 
Nuclease free dH2O Up to 20 μl 
  
Table 16: Primers used to generate reporter plasmids 
Plasmid Primer sequences 5' → 3' including restriction site 
pGL4.10-2733/+79 FP_ cccGGTACCgctgaggaaagaagaaaacaaca 
pGL4.10-2733/+79 RP_ cccAAGCTTctggcctcagtttccctttt 
pGL4.10-1915/+79 FP_ cccGGTACCagaccagggtgatgtcgaac 
pGL4.10-1455/+79 FP_ cccGGTACCtggcaagagctctaggagga 
pGL4.10-845/+79 FP_ cccGGTACCattggcaaggctgcagag 
pGL4.10-791/+79 FP_ cccGGTACCctgctgtgctgctggttaag 
pGL4.10-733/+79 FP_ cccGGTACCcgcatgctcacctttacctt 
pGL4.10-680/+79 FP_ cccGGTACCcctgtgttaaaaccctgggtatag 
pGL4.10-593/+79 FP_ cccGGTACCcccagccagcctactctaat 
pGL4.10-520/+79 FP_ cccGGTACCgcgcctagggccttactaac 
pGL4.10-168/+79 FP_ cccGGTACCgcatctctcccctctgtgtc 
pGL4.10-143/+79 FP_ cccGGTACCcccacgatgaggagagaaaa 
pGL4.10-125/+79 FP_ cccGGTACCaaaagaggggtgcctggtt 
pGL4.10-39/+79 FP_ cccGGTACCgcatctctcccctctgtgtc 
The same reverse primer was used to construct all plasmids. GGTACC, KpnI restriction site, 
AAGCTT, Hind-III restriction site.   
Table 17: List of sequencing primers used in this study 
Name                  Sequence       Region 
mTspo_Seq_F1 agattttggaagctgaggaaa -2744 to -2723 
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mTspo_Seq_F2 ggagggggaggactaaagaa -2403 to -2383 
mTspo_Seq_F3 gaccagggtgatgtcgaact -1914 to -1894 
mTspo_Seq_F4 ccactgagagggaagatgct -1412 to -1392 
mTspo_Seq_F5 ggcgcagagagactgaaaag -906 to -886 
mTspo_Seq_F6 gcgtgcacagaaagtactcc -425 to -405 
mTspo_Seq_R1  agagcttgccagatgtggtt -2598 to -2578 
mTspo_Seq_R2 ctgagccatttctccagctc -2083 to -2063 
mTspo_Seq_R3 ttcttgctacagcctgtggat -1599 to -1578 
mTspo_Seq_R4  gtgaaaccaagtgggaccag -1074 to -1054 
mTspo_Seq_R5 ccctcaacctcttcctgtga -569 to -549 
mTspo_Seq_R6 gacactgcgcacagaggtt -28 to -9 
 
2.2.3 Site directed mutagenesis 
MatInspector software (http://www.genomatix.de) was used to perform sequence 
analysis of all potential substitution mutants to ensure that the mutated sequence 
did not create a known consensus DNA binding motif. Thereafter, in-vitro site 
directed mutagenesis was performed by PCR using the Q5® site-directed 
mutagenesis kit, a mutagenic primer and plasmid pGL4.10-845/+79 as template. 
Custom non-overlapping mutagenic primers were designed using the 
NEBaseChanger tool (https://nebasechanger.neb.com/). Non-overlapping primers 
are preferred over complementary primers for mutagenesis since they minimize 
primer-primer interactions and therefore favor the use of plasmid DNA as the 
template (Liu and Naismith, 2008). Two to five bp mismatches in the core-binding 
motif of the transcription factor binding sites (TFBSs) were incorporated in the 
center of the forward primer. A PCR containing 12.5 µl of the Q5 hot start high-
fidelity 2x master mix, 1.25 µl (0.5 µM) of the forward and reverse primer, 1 µl 
(25 ng) of template DNA and 9 µl of nuclease free water in a total reaction volume 
of 25 µl was performed using the temperature profile outlined in the Table 18 below 
Table 18: Site directed mutagenesis PCR temperature profile 
Step Temperature Time 
Initial Denaturation 98 °C 30 seconds 
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25 cycles 
98 °C 
60-70 °C 
72 °C 
10 seconds 
30 seconds 
2 mins, 30 seconds 
Final Extension 72 °C 2 mins  
Hold  8 °C  
Annealing temperature: TFBSs Sp1.4, Ets.2 and Nkx 3.1/Sp1/3/4, 60 °C, TFBSs Ap-1, Ets.1, 
AR/PR, 66 °C, TFBSs Sp 1.1, Sp 1.2/3, 70 °C. 
  
The PCR products were then treated with a KLD (Kinase, Ligase and DpnI) 
enzyme mix in a reaction that included the following components; 1 µl of the PCR 
product, 5 µl of the 2x KLD reaction buffer, 1 µl of the 10x KLD enzyme mix and 3 
µl of nuclease free water. The ingredients were mixed well by pipetting up and 
down and incubated at room temperature (RT) for 5 mins. Five microliters of the 
KLD mix was then used to transform NEB 5-alpha competent E. coli cells (provided 
for in the kit) by heat shock. Plasmid DNA was isolated from single colonies using 
the NucleoSpin® Plasmid kit and sequenced to verify the mutations. E. coli hosts 
harboring the mutated variants were grown in LB medium containing 100 µg/ml 
ampicillin at 37 °C with vigorous shaking (170 rpm) overnight before plasmid DNA 
was extracted with using NucleoBond® Xtra Midi EF (endotoxin-free) kits 
(Macherey & Nagel, Dueren, Germany).  
2.2.4 Transient transfections, luciferase and β-Gal assays  
All transfections were performed in antibiotic free medium. Cells were seeded in 
12-well plates and left overnight for attachment and recovery. One hour prior to 
transfection, pre-warmed fresh medium was added to the cells. Transfection 
complexes were then prepared by mixing 0.5 µg of plasmid DNA (diluted in 5 µl of 
ddH20), 3 µl of TransIT-LT1 transfection reagent (Mirus, Madison, WI, USA) and 
100 µl of serum free medium. A second transfection mix containing 0.4 µg of the 
pSV beta-galactosidase control vector (Promega) was also prepared. The 
mixtures were vortexed and incubated at RT for 30 mins before being added 
dropwise to the cells. Where indicated, the compounds LPS and Trichostatin A 
(TSA) were added to cells in fresh medium 24 h post transfection and incubated 
for a further 6 h. LPS was added to the cells at 250 ng/ml final concentration. BV-
2 and ARPE-19 cells were treated with 50 and 200 nM of TSA respectively. After 
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time lapse, cells were washed once with 1x phosphate-buffered saline (PBS) and 
lysed in 250 µl of 1x Glo lysis buffer (Promega, Madison, WI, USA). Cell lysates 
were then transferred to a 1.5 ml microfuge tube and centrifuged for 3 mins at 
13000rpm. Luciferase activity was then determined by combining 40 µl of the 
lysates with 40 µl of the luciferase assay reagent (Promega) in a 96-well white flat-
bottom plate (Corning) and measuring light emission. For measurement of β-
galactosidase activity, 50 µl of β-galactosidase assay reagent was mixed with 
50 µl of the cell lysates and incubated at RT for 30 mins. One hundred and fifty 
microliters of stop solution (1M Na2CO3) was then added to the mixture and 
absorbance measured at 405 nm. Tecan Infinite F200 pro reader (Tecan, Austria) 
was used to measure both luminescence and light absorbance.   
2.2.5 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) was performed with the Magna ChIP™ G 
Kit according to the manufacturer's instructions with slight modifications. BV-2 cells 
were propagated in T-75 flasks until they reached ~80-90% confluence. The cells 
were then cross-linked at RT for 10 mins in 9 mls of serum free medium and 1 ml 
of complete fixation solution (Table 5). Final concentration for formaldehyde in the 
culture medium was 1%. Quenching of unreacted formaldehyde was done with 
1 ml of 10x glycine (provided in the kit) for 5 mins at RT. Thereafter, plates were 
washed thrice with ice cold 1X PBS supplemented with protease inhibitors (1 mM 
PMSF, 1 μg/ml aprotinin and 1 μg/ml pepstatin A) before being scraped and 
pelleted by centrifugation at 2000 x g for 5 min at 4 °C. Cell pellets from three 
flasks were resuspended in 0.5 mls of cell lysis buffer (provided in the kit) and 
incubated on ice for 15 mins with vortexing every 5 mins. The cell suspension was 
then centrifuged at 1000 x g for 5 mins at 4 °C and the supernatant discarded. The 
resulting cell pellet was resuspended in 0.5 mls nuclear lysis buffer (provided in 
the kit) containing protease inhibitors and kept on ice. Chromatin was sheared to 
an average size of 200–800 bp with a Vibracell 75115 Sonicator (Bioblock 
Scientific) using twelve 10 s pulses at 20% amplitude. Sheared chromatin was 
then transferred to fresh 1.5 mls microfuge tubes in 50 µl aliquots before 450 µl of 
dilution buffer (provided in the kit) containing protease inhibitors was added to 
each aliquot. Twenty microliters of protein G magnetic beads (provided in the kit) 
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was added to the diluted chromatin and immunoprecipitation performed with 2.5 
μg of anti-Pu.1, 4µg of Sp3, Sp4, cFos, Stat3 (Santa Cruz Biotechnology), Sp1 
and cJun (Abcam, Cambridge, UK) overnight at 4 °C with rotation. Protein G 
magnetic beads with the captured antibody/antigen immune complexes were 
separated from the immunoprecipitation fractions using a magnetic separation 
rack and subjected to a series of washing steps with provided buffers. Protein 
complexes were eluted from the magnetic beads with 100 µl of ChIP elution buffer 
(provided in the kit) containing proteinase K and reverse cross-linking performed 
by incubating in a thermoblock at 62 °C for 2 h with shaking. The 
immunoprecipitated DNA was purified and analyzed by PCR and qRT-PCR using 
primers specific for mouse Tspo proximal and distal promoter regions (Table 19). 
ChIP positive and negative controls included DNA precipitated with anti-RNA 
polymerase-II and normal mouse IgG (provided in the kit) respectively. QRT-PCR 
analysis of DNA immunoprecipitated with anti-RNA polymerase-II was performed 
using a positive control primer set that amplifies a 93 bp fragment in intron 5 of the 
mouse Gapdh gene (Active Motif, Carlsbad, CA, USA). For ChIP after LPS 
stimulation, BV-2 cells were grown in T-75 flasks until reaching ~ 80-90% 
confluency before being stimulated with 1 µg/ml LPS or 1 x PBS as vehicle for 1 h. 
Cross-linking was performed thereafter, and ChIP carried out using the same 
procedure described above. 
Table 19: Primer sequences (5' → 3') used in ChIP experiments 
 Forward Primer Reverse Primer 
Product 
size 
Distal 
promoter 
-832 to -694 bp 
cagaggtgtgctgagagatgt ctcagatcctggtgtctgca 138 bp 
Distal 
promoter  
-613 to -
477 bp 
cagattggtggggctccttg actaaccgctttctgcctct 136 bp 
Proximal 
promoter 
-314 to -196 bp 
agaattcagccaggcacagt cagaggtggcacatgtttgt 118 bp 
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2.2.6 RNA-Isolation and reverse transcription 
At the end of the culture experiments, old medium was removed, and the cells 
washed once with 1x PBS. Cell lysis was done with 350 µl of RA1 buffer 
supplemented with 3.5 µl of β-mercaptoethanol before total RNA was extracted 
using the NucleoSpin® RNA Mini Kit according to the manufacturer’s (Macherey 
& Nagel, Dueren, Germany) instructions. After purification, RNA was eluted from 
the silica-based columns with 40 µl of nuclease free water and the concentrations 
determined spectrophotometrically using a NanoDrop 2000 (Thermo Fisher 
Scientific). First strand cDNA synthesis was then performed with 1 µg of RNA in a 
20 μl final volume using the RevertAid™ H Minus First strand cDNA Synthesis Kit 
(Thermo Fisher Scientific). The resulting cDNA was diluted with nuclease free 
water to a final volume of 50μl (final conc. 20ng/µl) and used as a template for 
real-time PCR.  
2.2.7 Quantitative RT-PCR 
Real-time qPCR was performed in 10 µl final reaction volume by combining the 
components listed in Table 20. The reaction mixtures were then run using the 
temperature profile outlined in Table 21.    
Table 20: qRT-PCR recipe 
Reaction component Amount 
cDNA 50 ng (2.5 µl) 
Forward primer 1 µl (1 µM) 
Reverse primer 1 µl (1 µM) 
Fast Start Universal Probe Master (Rox) 5 µl (800 µM of total dNTP) 
dual-labelled UPL probe 0.125 μl 
Nuclease free dH2O 0.375 µl 
 
Table 21: qRT-PCR cycling conditions 
Step Temperature Time 
Initial Denaturation 95°C 10 mins 
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40 cycles 
95 °C 
60°C  
15 seconds 
60 seconds 
Hold  8 °C  
 
ATP synthase subunit-β (ATP5B) was used as internal control. Sequences of 
primers used and their corresponding UPL probe numbers are outlined in Table 
22. ChIP-qPCR analysis was performed in a reaction containing 1.5 µl of the 
immunoprecipitated DNA, 0.5 µl (500 nM) of the forward and reverse primer, 
12.5 µl of the GoTaq® qPCR Master Mix (Promega, Madison, WI, USA), 0.2 µl of 
the carboxy-X-rhodamine (CXR) reference dye and 9.8 µl of nuclease free water. 
PCR cycling conditions were as follows: 2 min 95 °C hold, followed by 40 cycles 
of 15 s 95 °C melt and 1 min 60 °C anneal/extension. Melting curve analysis (95 
°C for 15 s, and then 60 °C for 15 s until 95 °C) followed each qPCR run to verify 
that a single product has been amplified. All qPCR reactions were carried out in 
an Applied Biosystems 7900 HT Fast Real-Time PCR system (Applied 
Biosystems, Carlsbad, CA, USA).  
Table 22: Primer sets used for qRT-PCR 
Gene Forward primer (5' → 3') Reverse primer (5' → 3') UPL 
Probe # 
Sp1 atgcccctattgcaaagaca tggatgtgacaaatgtgctgt 103 
Sp3 ttgcacctgtcccaactgta tgttgcttctttttcccaaga 77 
Sp4 
cagggagttccagtaacaat
ca 
caggagctatagtagcttgtt
gga 
58 
Pu.1 ggagaagctgatggcttgg caggcgaatctttttcttgc 94 
cJun 
ccagaagatggtgtggtgtt
t 
ctgaccctctccccttgc 11 
cFos 
gggacagcctttcctactac
c 
agatctgcgcaaaagtcctg 67 
Stat3 gttcctggcaccttggatt caacgtggcatgtgactctt 71 
ATP5B ggcacaatgcaggaaagg tcagcaggcacatagatagcc 77 
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2.2.8 siRNA-mediated gene silencing  
All siRNAs used in the current study were ON-TARGETplus SMART pool siRNAs 
which combine four different siRNAs sequences per gene (Table 23) to reduce off-
target effects (GE Healthcare Dharmacon, Lafayette, CO, USA). The following 
ON-TARGETplus SMARTpool siRNAs were used: Sp1 (L-040633-02-0005), Sp3 
(L-040397-01-0005), Sp4 (L-043282-01-0005), Pu.1(Spi1) (L-041420-00-0005), 
cJun (L-043776-00-0005), cFos (L-041157-00-0005), Stat3 (L-040794-01-0005) 
and the non-targeting negative control pool (D-001810-10-05). One vial of 5 nM 
siRNA (in dry pellet form) was reconstituted using 250 µl of 1x siRNA buffer (diluted 
from a 5x stock solution with RNAse free water) to prepare 20 µM stock solutions 
which were stored in -20 °C until use. Transfection was carried out as described 
in a previous report (Rosner et al., 2010). BV-2 cells were plated at a density of 2 
x 105 cells per well in 12-well plates and left overnight for attachment and recovery. 
The next day and 30 mins before transfection, cells were washed once with 0.5 
mls of warmed Dulbecco's PBS (DPBS) and the medium changed to Opti-MEM I 
reduced serum media (900 µl per well). The siRNA/lipid complexes were then 
prepared by combining 5 µl of siRNA duplex (final concentration 100 nM), 3 µl of 
lipofectamine 3000 transfection reagent (Invitrogen) and 100 µl of Opti-MEM I 
medium and incubating for 20 mins at RT. The siRNA/lipid solutions were then 
added dropwise to each well and the cells incubated for 48 h for mRNA analysis. 
For ARPE-19 experiments, cells were seeded and grown until confluent before 
being transfected with 1 μg of the Sp1, Sp3 and Sp4 siRNA (Santa Cruz, 
Biotechnology) using lipofectamine 3000. For simultaneous knockdown of two 
genes, the amount of siRNA used per target gene was reduced by half to 50 nM 
and 0.5 µg for BV-2 and ARPE-19 cells respectively, thereby keeping the overall 
amount of siRNA per transfection constant. Twenty four hours post siRNA 
transfection, BV-2 and ARPE-19 cells were transfected with plasmid pGL4.10-
845/+79 and incubated for an additional 24 h prior to measuring luciferase activity. 
Table 23: ON-TARGETplus SMARTpool siRNA sequences 
Gene Target sequence (5′–3′) Antisense (5′–3′) Cat. No. 
Sp1 ACGCAGGACUCGUCGGGAA UUCCCGACGAGUCCUGCGU J-040633-21 
 GACAGUGAUUCCUGGAUUA UAAUCCAGGAAUCACUGUC J-040633-22 
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2.2.9 Western Blots  
BV-2 and ARPE-19 cells were seeded in 6-well plates at a density of 4 x 105 cells 
per well. For BV-2 cells, transfection with siRNA was performed 24 h later as 
earlier described. After 24 h, culture media was replaced, and the cells stimulated 
with 1 µg/ml LPS for an additional 72 h. For ARPE-19, cells plated in the 6-well 
plates were allowed to grow until confluency before being transfected with 1.5 μg 
 GAUCAUACCAGGUGCAAAC GUUUGCACCUGGUAUGAUC J-040633-23 
 GCUUAUGCUAAAUCGGUUA UAACCGAUUUAGCAUAAGC J-040633-24 
Sp3 CCUAACACAUUUACGAGUA UACUCGUAAAUGUGUUAGG J-040397-09 
 AAUCAAUAGUGUCGAUCUA UAGAUCGACACUAUUGAUU J-040397-10 
 AAACUCAAGUAGUCGCUAA UUAGCGACUACUUGAGUUU J-040397-11 
 CCGAUGGACAUUUGAUAAA UUUAUCAAAUGUCCAUCGG J-040397-12 
Sp4 GUACAAAACCCAAGCGGUA UACCGCUUGGGUUUUGUAC J-043282-9 
 GGAAGAAUUCUGAAACGUU AACGUUUCAGAAUUCUUCC J-043282-10 
 AGGGAUUGCUAAUGCGACA UGUCGCAUUAGCAAUCCCU J-043282-11 
 CUAACUGACAAUAGGGAUA UAUCCCUAUUGUCAGUUAG J-043282-12 
Pu.1 GGAUGUGCUUCCCUUAUCA UGAUAAGGGAAGCACAUCC J-041420-05 
 CCAUAGCGAUCACUACUGG CCAGUAGUGAUCGCUAUGG J-041420-06 
 GUCCAAUGCAUGACUACUA UAGUAGUCAUGCAUUGGAC J-041420-07 
 GCAAGACAGGCGAGGUGAA UUCACCUCGCCUGUCUUGC J-041420-08 
cJun CCAAGAACGUGACCGACGA UCGUCGGUCACGUUCUUGG J-043776-05 
 GCAGAGAGGAAGCGCAUGA UCAUGCGCUUCCUCUCUGC J-043776-06 
 GAAACGACCUUCUACGACG CGUCGUAGAAGGUCGUUUC J-043776-07 
 GAACAGGUGGCACAGCUUA UAAGCUGUGCCACCUGUUC J-043776-08 
cFos GCGCAGAGCAUCGGCAGAA UUCUGCCGAUGCUCUGCGC L-041157-05 
 GGAGGAGGGAGCUGACAGA UCUGUCAGCUCCCUCCUCC L-041157-06 
 GGAUUUGACUGGAGGUCUG CAGACCUCCAGUCAAAUCC L-041157-07 
 GCGCAGAUCUGUCCGUCUC GAGACGGACAGAUCUGCGC L-041157-08 
Stat3 CUCAGAGGGUCUCGGAAAU AUUUCCGAGACCCUCUGAG J-040794-09 
 CCGCCAACAAAUUAAGAAA UUUCUUAAUUUGUUGGCGG J-040794-10 
 GAGUUGAAUUAUCAGCUUA UAAGCUGAUAAUUCAACUC J-040794-11 
 CAGUUUACCACGAAAGUCA UGACUUUCGUGGUAAACUG J-040794-12 
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of Sp1, Sp3 and Sp4 siRNA (Santa Cruz, Biotechnology) for 72 h as earlier 
described. After incubation with siRNA, cells were washed once with ice-cold 
DPBS and lysed in 150 µl of 1x cold RIPA buffer (Table 5) supplemented with 
protease inhibitor cocktail (Roche). Protein concentration was estimated with the 
PierceTM Bicinchoninic Acid (BCA) Protein Assay Kit as per the manufacturer’s 
instructions. Briefly, albumin protein standard (provided for in the kit at a 
concentration of 2 mg/ml) was serially diluted to 1.5, 1.0, 0.75, 0.5, 0.25, 0.125 
and 0.025 mg/mL and the protein samples were diluted 1:20 with 1x RIPA buffer. 
25 µl of each standard or unknown sample was pipetted in a 96-well plate and 
combined with 200 µl of working reagent (50 parts of BCA Reagent A mixed with 
1 part of BCA Reagent B). The mixture was incubated at 37°C for 30 mins and 
after cooling to room temperature, absorbance was measured at 570 nm with a 
Tecan Infinite F200 pro reader (Tecan, Austria). Equal amounts of protein (~20 µg) 
and 8 µl of PageRuler pre-stained protein ladder (Thermo Scientific) were 
separated on 15% tris-glycine polyacrylamide gels at 100 V for 120 mins and then 
transferred onto 0.45 μm nitrocellulose membranes (Bio-Rad, Munich, Germany). 
The membranes were then placed in blocking solution (same as antibody solution 
listed in Table 5) for 1 h to prevent non-specific binding and afterwards probed 
with primary antibodies (Table 4) directed against TSPO (dilution 1:1000) and 
Actin (dilution 1:1000). Primary antibody incubations were done overnight on a 
rotating platform at 4 °C. The next day, the blots were washed thrice in TBS-T for 
15 mins before incubation with secondary goat anti-rabbit IgG-HRP (dilution 
1:4000) or rabbit anti-goat IgG-HRP (dilution 1:2500) antibodies for 1 h at RT. 
Membranes were developed with SignalFire™ Elite ECL reagent and protein 
bands visualized and imaged with the MultiImage II system (Alpha Innotech, Santa 
Clara, CA, USA). Band intensities were quantified using Image J software (NIH).   
2.2.10 Statistical analysis 
Statistical analysis was carried out with Prism Graph pad version 6.0 (GraphPad 
Software Inc., San Diego, CA) and a p value of < 0.05 was considered to be 
statistically significant. Relative changes in gene expression were calculated with 
the 2-ΔΔCt method to generate relative quantification (RQ) values which were 
subsequently analyzed by Prism Graph pad. For ChIP experiments, data obtained 
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by qRT-PCR for each specific antibody was normalized by subtracting the 
adjusted input (Ct input − Log2 (Input dilution factor)) values to obtain ΔCt values. 
ΔΔCt values were then calculated by subtracting the ΔCt value of negative control 
(IgG) from the ΔCt values of the target ChIP samples. Fold enrichment was 
subsequently calculated as 2 to the power of negative ΔΔCt values (2-ΔΔCt). 
Student’s t-test was used for two groups comparison, one-way ANOVA with 
Tukey’s post-hoc test for multiple group comparison and two-way ANOVA with 
Dunnett’s post-hoc test for multiple group comparisons involving two factors. The 
data are expressed as mean ± standard deviation (SD) unless indicated otherwise. 
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3.0 Results 
3.1 Basal activity of the Tspo promoter in BV-2 microglia 
A 2.812Kb Tspo promoter region, including 79 bp downstream of the previously 
mapped transcription initiation site (Giatzakis and Papadopoulos, 2004), was 
amplified by PCR using Mouse BAC clone RP23-352L10 (RPCI) as template. 
The amplified PCR fragments were directionally cloned into the promoter-less 
pGL4.10-Basic firefly luciferase reporter vector using KpnI and Hind-III restriction 
sites to generate plasmid pGL4.10–2733/+79. Sequencing was carried to confirm 
that the cloned constructs had the correct reading frame and were in correct 
orientation. Thereafter to dissect cis-regulatory elements that are critical for Tspo 
promoter activity in microglia, unidirectional 5’ deletions of the promoter 
sequence were introduced using PCR to generate plasmids pGL4.10-1915bp, 
1455bp, 845bp, 520bp, 168bp, and pGL4.10-39bp. The activity of the reporter 
plasmids was then investigated in the BV-2 mouse microglia cell line. To control 
for transfection efficiency, cells were co-transfected with pSV-β-Galactosidase 
control vector. As shown in figure 10A, transfection of plasmid pGL4.10–
2733/+79 resulted in consistently high promoter activity in BV-2 cells on the order 
of 150–200 times the background measured using the promoterless plasmid. No 
significant differences (p > 0.05) in promoter activity could be detected between 
cells transfected with the reporter vector containing either the first 845 bp of the 
Tspo promoter or the full-length promoter (pGL4.10–2733/+79). These results 
implied that the minimal promoter required to reconstitute near maximal activity 
in BV-2 cells was contained in the first 845 bp upstream of the transcription start 
site (TSS). Additional deletions from -845 to -520 bp and from -168 to -39 bp led 
to a significant decrease in promoter activity, suggesting the presence of positive 
regulatory elements in these regions. To further localize the positive regulatory 
sequences in these regions, 6 additional constructs (pGL4.10-797, -733, - 680, -
593, -145, and pGL4.10-125) were generated; 4 between -845 and -520bp 
(pGL4.10-797, 733, -680 and pGL4.10-593) and 2 between -168 and -39 
(pGL4.10-145 and pGL4.10-125). Deletion of the area between -845 to -593 
resulted in a significant loss of promoter activity. Notably, subsequent deletion to 
nucleotide −520 resulted in a striking decrease in promoter activity, suggesting 
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that most of the positive regulatory elements are likely localized between this 
region (Figure 10B). Moreover, deletion of sequences between -125 and -39 
decreased promoter activity to near baseline levels, implying that additional 
factors necessary for eliciting basal transcriptional activity are contained in this 
region.    
 
Figure 10: Functional characterization of the mouse Tspo promoter. BV-2 cells were 
transfected with equimolar amounts of the various 5'-deletion constructs and 24 h later 
they were lysed, and their luciferase activity measured. Luciferase activity is shown as 
fold over background obtained with pGL4.10-basic. (A) -845 bp upstream constitutes the 
minimal promoter region required to drive near maximal promoter activity in BV-2 cells. 
Deletion of sequences between -845 and -520 bp and between -168 and -39 bp results 
in a significant loss in promoter activity. # #p < 0.01, #p < 0.05, ****p < 0.0001 vs. full (-
2733/+79) promoter. (B) Additional reporter plasmids were constructed to localize 
positive regulatory elements between the -845-520 and -168-39 regions. Deletion of the 
-593−520 area led to a dramatic decrease in promoter activity, implying that most of the 
positive regulatory elements were likely localized between this region. Deletion of the -
125−39 sequences abolished promoter activity. Error bars represent SD from three 
independent biological replicates each measured in duplicate. # # # #p < 0.0001, ****p < 
0.0001 vs. -845/+79 promoter.  
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3.2 LPS stimulation increases Tspo promoter activity 
In our previous research, we have demonstrated that lipopolysaccharide (LPS) 
strongly induces Tspo mRNA and protein levels in BV-2 microglia cells 
(Karlstetter et al., 2014b). Therefore, the current study set out to investigate 
whether the LPS-induced increase in Tspo expression is transcriptionally 
mediated. To this end, BV-2 cells were transfected with the luciferase reporter 
plasmids for 24 h after which old medium was changed, and the cells stimulated 
with 250 ng/ml LPS for an additional 6 h. Our findings demonstrated that cells 
transfected with the reporter plasmid containing the full-length promoter 
(pGL4.10–2733/+79) exhibited up to 3-fold increase in luciferase activity upon 
LPS exposure when compared to the unstimulated controls. Similarly, the 
luciferase activity of cells transfected with reporter plasmids containing promoter 
sequences between -845 to -593 was significantly increased following LPS 
stimulation. Of note, the effect of LPS on Tspo promoter activity in the BV-2 cells 
was abolished when sequences between -593– 520 bp were deleted (Figure 11), 
suggesting that these sequences harbour cis-acting regulatory elements that 
drive Tspo expression in response to pro-inflammatory stimuli.       
 
Figure 11: LPS significantly induces Tspo promoter activity. BV-2 cells were 
transfected with equimolar amounts of the various 5'-deletion constructs for 24 hrs, then 
stimulated with LPS 100ng/ml for an additional 6 hrs. Values are derived from three 
biological replicates measured each measured in duplicate. ****p < 0.001, *p < 0.05 
 
  Results 
61 
 
3.3 Ap-1, Ets and Sp binding sites are strong positive elements 
regulating the expression of Tspo in BV-2 microglia  
Next, to localize strong positive elements in the identified regulatory regions, in-
silico analysis was performed using MatInspector software 
(http://www.genomatix.de). Bioinformatic analysis of the promoter revealed the 
presence of numerous putative TFBS; far too many to all have biological 
relevance. Therefore, comparison to previous Tspo promoter characterization 
studies in non-immune cells as well as screening for transcription factors 
implicated in the immune response was done to identify TFBS likely to be 
functional. Two consensus motifs for Ets (v-ets erythroblastosis virus E26 
oncogene homolog) binding sites, a half consensus motif for 
androgen/progesterone receptors, one Ap-1 motif, one motif for Nkx3.1 which 
has previously been shown to serve as a non-canonical binding site for Sp1/3, 
and four Sp1/3/4 consensus motifs (GC boxes) located in a CpG island 125 bp 
upstream of the TSS (Figure 12) were identified.  
Figure 12: Regulatory DNA sequences within the Tspo promoter. (A) Part of exon 1 
sequences are included and shown in capital letters and in bold. TSPO transcriptional 
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start site (TSS-1) is highlighted in red and the core central motifs of the putative 
transcription factor binding sites are highlighted with grey boxes. (B). Schematic 
representation of the minimal TSPO promoter and putative transcription factor binding 
sites essential for transcriptional activity in BV-2 cells. 
To determine the role of these of cis-acting elements in the regulation of Tspo 
promoter activity in BV-2 microglia, we used the plasmid pGL4.10-845/+79 to 
construct a series of substitution mutants. For each mutant plasmid, 2-5 bp in the 
core biding motif of the TFBS were exchanged for mutated sequences as 
described earlier in the methods section (Figure 13).  
Figure 13: Sanger sequencing validation of the introduced mutations 
As shown in figure 14A, compared to the wild-type construct, mutation of the 
overlapping 2nd and 3rd  Sp1/3/4 binding sites, termed as Sp1.2/3 in a previous 
report (Giatzakis and Papadopoulos, 2004) markedly reduced Tspo promoter 
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activity by around 96% (Fig. 9). Mutation of the other two GC boxes in the 
proximal promoter, Sp1.4 and Sp1.1, and of Ap-1, Ets.2 (2nd Ets site further 
downstream) and Nkx3.1/Sp1/3 site also resulted in significant loss in promoter 
activity compared to the wild type control. However, since site-directed 
mutagenesis of the Ap-1 or Ets.2 sites in the Tspo promoter alters a Stat3 binding 
site that occurs on the complementary strand spanning Ap-1 and Ets.2 sites in 
the -593-520 region (Batarseh et al., 2011), it is plausible that part of the decrease 
in promoter activity following Ap-1 or Ets.2 mutation might emanate from 
disruption of the Stat3 binding site. Furthermore, due to the close proximity of the 
Ap-1 and Ets.2 site (3 bp apart), we also generated a plasmid carrying mutations 
in both sites to investigate possible interactions. However, no synergistic effects 
on promoter activity were observed when both Ap-1 and Ets.2 sites were mutated 
(Figure 14B). Mutation of the AR/PR site in this cell line resulted in a significant 
increase in promoter activity. These results suggest that the GC boxes, Ap-1, 
Ets.2 and Nkx3.1 sites are essential for basal transcriptional activity of the -
845/+79 minimal promoter in BV-2 microglia cells.  
To examine whether the same transcription factor binding sites were crucial for 
Tspo transcriptional activity in other myeloid derived immune cells, substitution 
mutants were transfected into the mouse macrophage cell line, RAW 264.7. Our 
findings closely mirrored those obtained from BV-2 cells. Mutation of Sp1.1, 
Sp1.2/3, Nkx3.1/Sp1/3, Ets.2, Ap-1 but not Sp1.4 led to significant decreases 
(p < 0.001) in promoter activity when compared to the wild type control (Figure 
14C). Similarly, mutation of the AR/PR site led to a slight but non-significant 
increase in promoter activity. These results demonstrate that Ap-1, Ets.2, 
Nkx3.1/Sp1/3 and Sp1/3/4 binding sites on the promoter are were important for 
a myeloid lineage-dependent transcriptional control of Tspo. 
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Figure 14: Ap-1, Ets.2, Nkx3.1/Sp1/3 and the conserved GC boxes in the proximal 
promoter are crucial for TSPO promoter activity. (A) A series of luciferase reporter 
plasmids carrying mutations in the core motifs of the potential regulatory elements within 
the positively identified regulatory regions were constructed using the −845/+79 plasmid 
as template. The wildtype and mutant reporter plasmids were then transiently transfected 
into BV-2 cells. After 24 h, the cells were harvested, and luciferase activity measured (B) 
Due to the proximity of the Ap-1 and Ets.2 site (3 bp apart) on the Tspo promoter, a 
plasmid carrying mutations in both sites was constructed. BV-2 cells were transfected 
with equimolar amounts of the indicated reporter constructs for 24hrs, and their luciferase 
activity measured. No synergistic effects on promoter activity were observed when both 
Ap-1 and Ets.2 sites were mutated. (C) RAW 264.7 macrophage cells were transfected 
with wildtype and the generated mutant reporter plasmids for 24 h after which the cells 
were harvested, and luciferase activity measured. Luciferase activity is shown as fold 
over background obtained with pGL4.10-basic. Error bars represent the SD from two 
independent biological replicates each measured in duplicate. ****p < 0.0001, ***p < 
0.001 vs wild type promoter -845/+79. 
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3.4 Pu.1, cJun, cFos, Stat3, Sp1, Sp3 and Sp4 binds the 
endogenous Tspo promoter in BV-2 microglia  
Based on the distinctly different Tspo expression in microglia cells in the CNS 
including the retina, we sought to investigate using chromatin 
immunoprecipitation (ChIP) whether microglia specific factors are bound to the 
endogenous Tspo promoter in BV-2 cells. Since Pu.1 is largely responsible for a 
microglia specific gene expression signature (Crotti and Ransohoff, 2016) and 
that mutation of an Ets consensus binding site on the Tspo promoter results in a 
significant loss in promoter activity, we sought to determine whether Pu.1 binds 
the Ets sites on the endogenous promoter in intact BV-2 cells. To this end, 
formaldehyde cross-linked chromatin from BV-2 microglia was 
immunoprecipitated with a specific antibody against Pu.1 and the 
immunoprecipitated DNA subjected to PCR analysis following reverse-cross 
linking and purification steps. Findings from both ChIP-PCR and ChIP-qPCR 
experiments revealed that the Ets.2 site, located in the -593-520 region, but not 
Ets.1 found further upstream in the Tspo promoter, is bound by Pu.1 (Figure 15). 
These results corroborated our initial site directed mutagenesis findings that 
mutation of the Ets.2 site, but not the Ets.1 site significantly reduced Tspo 
promoter activity in both BV-2 microglia and RAW 264.7 macrophages. 
We next tested using ChIP whether Sp1, Sp3, Sp4, cJun, cFos, and Stat3 binds 
to their respective TFBS on the endogenous Tspo promoter in BV-2 microglia 
cells. Our data demonstrates that both the proximal promoter harboring sites 
Sp1.4, Sp1.2/3 and Sp1.1, and the Nkx3.1 site which also serves as a non-
canonical site for Sp family of GC box binding proteins (Giatzakis and 
Papadopoulos, 2004)  are highly enriched for Sp1, Sp3 and Sp4 proteins (Figure 
16). Similarly, the Ap-1 and Stat3 sites were enriched for cJun, cFos, and Stat3 
proteins (Figure 16). 
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Figure 15: Pu.1 binds to the endogenous Tspo promoter in BV-2 microglia. (A) 
Crosslinked, sheared chromatin was prepared from BV-2 cells and immunoprecipitated 
with antibodies specific for Pu.1. Precipitated DNA was amplified by PCR with primers 
spanning the first (-832-694) and second Ets sites (-613 to -477) on the Tspo promoter 
(Table 4). Products were visualized on a 1% agarose-gel. Input represents PCR products 
obtained from the chromatin samples before immunoprecipitation and served, together 
with genomic DNA (gDNA), as a positive control. Normal rabbit IgG served as a negative 
control. ChIP DNA was substituted for water in the non-template control (NTC) reactions. 
The images shown are representative of 3 independent experiments (B) ChIP DNA was 
amplified by qRT-PCR using the same primers outlined in Table 4. Data is presented as 
mean ± SD of at least three biological replicates and expressed as fold-enrichment 
calculated as described earlier in Methods. (C) Schematic diagram illustrating Pu.1 
occupancy in the second, but not first, Ets site on the Tspo promoter. 
3.5 LPS induces Pu.1, cJun, cFos, Sp1, Sp3 and Sp4 
recruitment to the Tspo promoter in BV-2 microglia 
Given that LPS strongly induced Tspo promoter activity in BV-2 cells with 
concomitant increase in Tspo mRNA and protein levels (Karlstetter et al., 2014a), 
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we sought to investigate whether this induction involves the additional recruitment 
of transcription factors to the Tspo promoter. For this, BV-2 cells in T-75 flasks 
were stimulated with 1 µg/ml LPS for 1 h after which the cells were cross-linked 
with 1% formaldehyde and subjected to ChIP analysis as described in the 
methods section. ChIP-qPCR analysis of immunoprecipitated DNA demonstrated 
that Pu.1, cJun, cFos, Sp1, Sp3 and Sp4 occupancy at the Tspo promoter was 
significantly (p < 0.05) enhanced following LPS stimulation (Figure 16). In 
contrast, Stat3 binding to the Tspo promoter was not LPS inducible, implying that 
the enhanced binding of Ap-1 and Pu.1 to the Tspo promoter may influence Stat3 
binding to this partially overlapping site (Figure 16). 
 
Figure 16: LPS stimulates recruitment of transcription factors Pu.1, Ap-1 (cJun/ 
cFos) Sp1, Sp3 and Sp4 to the endogenous Tspo promoter in BV-2 microglia. BV-
2 cells were stimulated with 1 μg/ml LPS or 1x PBS for 1 h before crosslinking and 
chromatin shearing. Sheared chromatin was immunoprecipitated with antibodies specific 
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for Pu.1, cJun, cFos, Stat3, Sp1, Sp3, Sp4 and RNA polymerase-II. Precipitated DNA 
was amplified by qRT-PCR with primers spanning -613-477 (distal) and -314-196 
(proximal) regions on the Tspo promoter (Table 4). DNA precipitated with anti-RNA 
polymerase-II was analyzed by qRT-PCR using a positive control primer set that 
amplifies a 93 bp fragment in intron 5 of the mouse Gapdh gene. Data is presented as 
mean ± SD of at least three biological replicates and expressed as fold-enrichment 
calculated as described earlier in Methods. Normal mouse IgG served as a negative 
control. #p < 0.05, # #p < 0.01. *p < 0.05, **p < 0.01, ***p < 0.001.  
3.6 Pu.1, Sp1, Sp3, Sp4, cJun, cFos and Stat3 siRNA 
significantly reduce Tspo promoter activity in BV-2 
microglia  
To determine the role of Pu.1, cJun, cFos, Stat3, Sp1, Sp3, and Sp4 in regulating 
Tspo promoter activity, RNAi mediated gene silencing was performed. The 
knockdown efficiency was verified at the mRNA level by qPCR (Figure 17A). As 
shown on figure 17C, down-regulation of Pu.1, cJun, cFos, Sp1, Sp3, Sp4 and 
Stat3 by siRNA transfection strongly diminished (p < 0.0001) Tspo promoter 
activity in BV-2 cells. No synergistic effects were observed when some of the 
siRNA pools were combined. These results further suggested that these 
transcription factors may participate in the regulation of Tspo expression in BV-2 
microglia cells.   
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Figure 17: Pu.1, cJun, cFos, Stat3, Sp1, Sp3 and Sp4 regulate Tspo promoter 
activity in BV-2 microglia cells. (A) BV-2 cells were transfected with 100nM of the 
indicated siRNAs for 48 h, and levels of Pu.1, cJun, cFos, Stat3, Sp1, Sp3 and Sp4 
mRNA were quantified using real time PCR. Data are derived from three independent 
experiments performed in duplicate and presented as mean ± SD. (B) Schematic 
representation of experimental setup (C) BV-2 cells were transfected with 100nM of 
siRNA in 12-well plates and 24 h later, transfected with the pGL4.10-845/+79 reporter 
construct and the pSV β-gal control vector for an additional 24 h prior to measurement 
of luciferase activity. Data are derived from two independent experiments performed in 
triplicate and presented as mean ± SEM. *p <0.05, **p <0.01, ***p <0.001, ****p <0.001 
3.7 Ap-1 mediates LPS-induced increase in Tspo protein 
expression in BV-2 microglia  
Because we observed that down-regulation of Pu.1, cJun, cFos, Stat3, Sp1, Sp3, 
and Sp4 significantly reduced Tspo promoter activity in BV-2 cells, we next set 
out to determine whether siRNA-mediated inhibition of these transcription factors 
could influence Tspo expression in BV-2 microglia. In this experiment, cells 
seeded in 6-well plates were transfected with 100nM siRNA for 72 h before 
harvesting in RIPA lysis buffer and analyzing Tspo expression via western blots. 
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Our findings revealed that under basal conditions, RNAi mediated gene silencing 
of these transcription factors did not alter Tspo protein expression in BV-2 cells. 
In contrast, a combined depletion of cJun and cFos blocked LPS induced 
increase in Tspo protein expression in BV-2 microglia (Figure 18), strongly 
suggesting that the dimeric transcription factor Ap-1 plays an instrumental role in 
the upregulation of Tspo in microglia during pathophysiological conditions.    
 
Figure 18: LPS-induced expression of Tspo in BV-2 cells is mediated by Ap-1. (A) 
Stimulation of BV-2 microglia with LPS leads to the induction of Tspo protein levels. Cells 
were stimulated with 1µg/ml LPS for 72 h after which they were lysed and Tspo protein 
levels analyzed by western blot analysis (B) Combined knockdown of cJun/cFos inhibits 
LPS induced increase in Tspo protein expression in BV-2 microglia. Cells were 
transfected with 100nM of siRNA pools for 24 h before change of medium and stimulation 
with 1µg/ml LPS for an additional 72 h. (C) The densitometry of each band was measured 
using Image J software (NIH), and values obtained from Tspo bands were normalized to 
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Actin. Data are derived from three independent immunoblots and presented as mean ± 
SD. *p <0.05. 
3.8 Differential utilization of the Tspo promoter between BV-2 
microglia and ARPE-19 cells  
We have previously shown that unlike microglia cells which express very low 
levels of Tspo during homeostasis, retinal pigment epithelial (RPE) cells express 
constitutively high levels of Tspo in the retinal tissue (Scholz et al., 2015a). 
Therefore in the current study, we explored whether the differential regulation of 
Tspo expression in microglia and RPE cells in the retina was a direct 
consequence of differential promoter usage between the two cell types. To this 
end, ARPE-19 cells were transfected with our series of reporter plasmids carrying 
Tspo promoters with progressive 5’-truncations and their luciferase activity 
compared with that in BV-2 microglia. As shown in figure 9, the proximal promoter 
retained very high activity in ARPE-19 cells, with as little as 125 bp of 5’-flanking 
sequence required for near maximal promoter activity (Figure 19A). These 
findings were in stark contrast to our earlier findings in BV-2 microglia cells where 
845 bp upstream of the TSS were needed for near maximal promoter activity 
(Figure 10A). Indeed, comparison of relative promoter activity (expressed as a 
percentage of the -845/+79 promoter activity) of constructs -168/+79, -143/+79, -
125/+79 and -39/+79 clearly revealed that the proximal promoter was 
preferentially very active in ARPE-19 cells when compared to BV-2 (Figure 19B). 
These results indicated that the first 125 bp upstream of the TSS contained all 
the core promoter elements necessary to direct TSPO transcription in ARPE-19 
cells.  
In-silico analysis had earlier identified a series of four GC boxes in this region, 
two of which were overlapping (Sp1.2/3 site). Of note is that these GC-boxes are 
highly conserved between humans and mouse (Batarseh et al., 2012a). 
Therefore, we sought to determine whether these GC boxes in the proximal 
promoter were specifically required for TSPO promoter activity in ARPE-19. For 
this, cells were transfected with reporter plasmids carrying 2-3 bp substitution 
mutations in the core binding motif of the various GC boxes. Our results 
demonstrate that mutations targeting either of the GC boxes significantly reduced 
Tspo promoter activity in ARPE-19 cells, with the greatest loss in activity 
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observed in mutations targeting the overlapping GC boxes (Figure 20A). 
Consistent with these findings, siRNA-mediated silencing of GC box binding 
proteins Sp1, Sp3 and Sp4 significantly lowered Tspo promoter activity in ARPE-
19 cells, with Sp1 knockdown evoking the greatest loss in promoter activity when 
compared to Sp3 or Sp4 (Figure 20B). 
 
Figure 19: Functional characterization of the Tspo promoter in ARPE-19 cells. (A) 
Cells were transfected with equimolar amounts of the various 5'-deletion constructs and 
24 h later they were lysed, and their luciferase activity measured. Luciferase activity is 
shown as fold over background obtained with pGL4.10-basic. As few as 125 bp of 
flanking sequence is needed to achieve near maximal promoter activity in ARPE-19 cells. 
**p < 0.01, ****p < 0.0001 vs. -2733/+79 promoter. (B) Comparison of proximal promoter 
activity between ARPE-19 and BV-2 cells. Promoter activity obtained from the indicated 
reporter constructs was calculated as a percentage relative to the -845/+79 construct. 
Error bars represent SD from three independent biological replicates each measured in 
duplicate. ****p < 0.0001, ***p < 0.001 vs. -845/+79 promoter.    
To ascertain the role of Sp1, Sp3 and Sp4 in the regulation of TSPO expression 
in ARPE-19 cells, siRNA mediated knockdown effects were analyzed at protein 
level. ARPE-19 cells seeded in 6-well plates were transfected with 1.5 µg of Sp1, 
Sp3 and Sp4 siRNA (either singly or in combination) and incubated for 72 h 
before harvesting protein and analyzing TSPO expression via western blots. Our 
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results revealed that individual knockdowns of Sp3 or Sp4 effectively reduced 
(p = 0.0062) TSPO protein levels when compared to the non-targeting scrambled 
control (Figure 20C). Sp1 knockdown also induced low to moderate decreases in 
TSPO protein levels, although these differences were not statistically significant. 
Notably, the simultaneous knockdown of either Sp1/Sp3, Sp1/Sp4 or Sp3/Sp4 
resulted in a prominent reduction in TSPO protein levels, implying overlapping 
and/or compensatory mechanisms for Sp family of GC box-binding factors in the 
regulation of TSPO in ARPE-19 cells. Taken together, these results indicate that 
the minimal promoter region for driving TSPO expression in RPE cells is located 
within a 125 bp region upstream of the TSS and that the GC boxes contained in 
this region have to be intact for full transcriptional activity.  
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Figure 20: GC box binding proteins Sp1, Sp3 and Sp4 regulate TSPO 
transcriptional activity in ARPE-19 cells. (A) Luciferase reporter plasmids carrying 
mutations in the core motifs of the GC boxes located in the Tspo proximal promoter (-
125 bp upstream) were constructed using the −845/+79 plasmid as template. The 
wildtype and mutant reporter plasmids were then transiently transfected into ARPE-19 
cells and 24 h later, the cells were harvested and luciferase activity measured. Data are 
derived from three independent experiments performed in triplicate. ****p < 0.001 vs. vs 
wild type promoter -845/+79 (B) ARPE-19 cells were transfected with 1 µg of siRNA in 
12-well plates and 24 h later, medium was changed, and the cells transfected with the 
pGL4.10-845/+79 reporter construct and the pSV β-gal control vector for an additional 
24 h. Cells were lysed 24 h later and luciferase activity measured. Data are derived from 
three independent experiments performed in triplicate. **p < 0.01, ***p < 0.001, ****p 
< 0.001 vs. non-targeting scrambled siRNA (C) ARPE-19 cells were transfected with 1.5 
µg of siRNA in 6-well plates for 72 h after which they were lysed and Tspo protein levels 
analyzed by western blot analysis. The densitometry of each band from three 
independent immunoblots was measured using Image J software (NIH), and values 
obtained from TSPO bands were normalized to Actin. Data are presented as mean ± 
SD. *p < 0.05, **p < 0.01 vs. non-targeting scrambled siRNA (D) Levels of TSPO, SP1, 
SP3 and SP4 mRNA in SV-40 microglia and ARPE-19 cells were quantified using real 
time qPCR. Data are derived from two independent experiments performed in duplicate 
and presented as mean ± SD. **p < 0.01, ***p < 0.001, ****p < 0.001.  
Lastly, we investigated whether the higher strength of the proximal promoter and 
the enhanced expression of TSPO in RPE cells when compared to microglia 
could be attributed to differential levels of GC box binding Sp factors between the 
two cell lines. For this experiment, human SV-40 immortalized microglia cell line 
was used to avoid species related differences. Real time qPCR analysis revealed 
that contrary to our expectations, SV-40 microglia cells expressed significantly 
higher levels of Sp1, Sp3 or Sp4 when compared to ARPE-19 cells, indicating 
that the differential activity of the Tspo proximal promoter between RPE and 
microglia cells could not be explained by differential levels of Sp factors.  
3.9 Trichostatin A (TSA) can induce Tspo promoter activity in 
ARPE-19 cells but not in BV-2 microglia 
Previous studies have demonstrated that Trichostatin A (TSA), a histone 
deacetylase (HDAC) inhibitor, could induce the recruitment of Sp1 and Sp3 to 
promoter regions (Huang et al., 2005; Kuan et al., 2016; Schnur et al., 2007; Won 
et al., 2002). Therefore, to further verify the contribution of GC box binding Sp 
proteins in the regulation of Tspo promoter activity, BV-2 and ARPE-19 cells were 
transfected with the reporter plasmids for 24 h and later stimulated with 50nM 
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and 200nM of TSA for 6 h and 24 h respectively. Our results demonstrate that 
TSA can significantly boost Tspo promoter activity in ARPE-19 cells, but not in 
BV-2 microglia (Figure 21). Infact, TSA induced a significant loss of promoter 
activity in the -845/+79 deletion construct in BV-2 cells. These results were 
consistent with our earlier findings and suggested that BV-2 cells, unlike ARPE-
19, require additional cis-acting regulatory elements and factors upstream for 
inducible Tspo promoter activity. 
 
Figure 21: TSA induces TSPO promoter activity in ARPE-19 but not in BV-2 cells. 
ARPE-19 and BV-2 cells were transfected with equimolar amounts of the indicated 
deletion constructs and 24 h later, medium was changed, and the cells treated with 
200nM and 50nM of the histone deacetylase inhibitor Trichostatin A for 24 h and 6 h 
respectively. Cells were later lysed and their luciferase activity measured. Data are 
derived from three independent experiments performed in triplicate and presented as 
mean ± SEM.  #p <0.05, ****p <0.001. 
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4.0 Discussion  
Since its initial discovery in 1977 as a secondary binding site for benzodiazepine 
anxiolytic drugs (Braestrup et al., 1977), multiple studies, including our own, have 
demonstrated that the Translocator protein (18kDa; TSPO) is a reliable biomarker 
of inflammation in the CNS including the retina (Daugherty et al., 2013; Karlstetter 
et al., 2014b; Scholz et al., 2015b; Wang et al., 2014). TSPO expression is 
strongly induced in numerous neuropathological conditions including 
Alzheimer’s, Parkinson’s, Multiple sclerosis, HIV encephalitis as well as 
neurodegenerative diseases of the retina (Cosenza-Nashat et al., 2009; 
Daugherty et al., 2013; Karlstetter et al., 2015; Yasuno et al., 2008). 
Immunohistochemistry studies show that increased TSPO expression during 
CNS pathology is concentrated in reactive microglia/infiltrating macrophages, 
while increased expression of diazepine binding inhibitor protein (DBI), an 
endogenous TSPO ligand, is concentrated in macroglia cells (Müller cells and 
astrocytes (Christian and Huguenard, 2013; Karlstetter et al., 2014b; Wang et al., 
2014). Importantly, we and others have shown that the interaction between TSPO 
and its endogenous or synthetic ligands limits the magnitude of microglia 
mediated inflammatory responses with concomitant neuroprotection (Scholz et 
al., 2015b; Wang et al., 2014). However, despite its importance as a biomarker 
and as an attractive therapeutic target for immunomodulation of microglia, studies 
focused on understanding the underlying molecular mechanisms of TSPO gene 
regulation in immune cells remain largely non-existent. Research carried out so 
far aimed at understanding TSPO’s transcriptional regulation has been 
conducted using steroidogenic and non-steroidogenic cell lines (Batarseh et al., 
2011, 2012a; Giatzakis and Papadopoulos, 2004). As such, findings from these 
studies have mostly attributed TSPO regulation to ubiquitous transcription factors 
such as Sp1, Sp3 and GABP which by themselves cannot confer microglia 
specific expression (Christoforos et al., 2008; Giatzakis and Papadopoulos, 
2004). To address this, we have performed an extensive functional analysis of 
the Tspo promoter in BV-2 cells in an attempt to identify important cis-regulatory 
elements and trans-acting factors required for both basal and inducible Tspo 
expression in microglia cells.  
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In the current study, the full length Tspo promoter was cloned into the pGL4.10-
Basic reporter vector upstream of the luciferase gene. Then, to identify the 
minimal promoter, a series of 5’-unidirectional truncation mutants were generated 
by PCR and transfected into BV-2 murine microglia cells. These cells were 
previously generated by infecting primary microglial cell cultures with a raf/myc 
oncogene carrying retrovirus, and represents the most extensively used cell line 
in microglial research (Blasi et al., 1990; Henn, 2009). Transfection of BV-2 cells 
with the reporter vector containing the full-length promoter resulted in consistently 
high luciferase activity, in the order of 150–200 times the background measured 
using the promoterless plasmid. Deletion of promoter sequences between -2733 
(full promoter) and −845 resulted in no significant difference in promoter activity, 
implying that approximately 845 bases upstream of the transcription start site 
were enough to activate near maximal Tspo transcription in microglia. Thus, for 
the remainder of the study, we analyzed the regulatory mechanisms acting on the 
−845/+79 construct. Deletion of only 73 bp from the −593/+79 construct resulted 
in a striking decrease in basal promoter activity to levels close to background, 
implying that strong positive cis-regulatory elements are likely localized in this 
region. Interestingly, deletion of the same region (-593 to -520) led to a significant 
loss in LPS induced promoter activity, suggesting that this region also harbours 
cis-acting regulatory elements that drive induced Tspo expression in response to 
LPS stimulation. Computer based analysis (MatInspector) of these promoter 
sequences revealed the existence of one Ap-1, Ets and Nkx3.1 site previously 
shown to bind Sp1/Sp3 factors in murine MA-10 Leydig cells and NIH-3T3 
fibroblasts (Giatzakis and Papadopoulos, 2004). Notably, Tspo promoter activity 
decreased significantly upon targeted point mutations of these TFBSs, indicating 
that these consensus binding motifs must be intact for full basal promoter activity 
in BV-2 microglia cells. Similar results were obtained when RAW 264.7 murine 
macrophage cells were transfected with wild-type or Ap-1, Ets.2 or 
Nkx3.1/Sp1/3/4 mutant reporter constructs, implying that the same TFBS’s are 
required for Tspo promoter activity in other myeloid derived cells. Simultaneous 
mutagenesis of Ap-1 and Ets.2 core motifs, which lie 3 bp apart, had no additive 
effect, implying that only one of the two sites may be utilized at any time, at least 
during basal conditions. 
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Microglia cells display distinct expression of TSPO when compared to other CNS 
cell types (Guilarte et al., 2016; Karlstetter et al., 2014b; Rupprecht et al., 2010). 
In the normal CNS milieu, quiescent microglia express very low levels of TSPO 
as opposed to reactive microglia in the diseased CNS which express strikingly 
elevated levels (Karlstetter et al., 2014b; Scholz et al., 2015b). In the current 
study, we demonstrate that the induction of Tspo by reactive microglia during 
pathophysiological conditions is mediated at the transcriptional level. 
Furthermore, congruent with the distinct Tspo expression pattern in microglia, we 
demonstrate for the first time that the essential myeloid lineage determining 
transcription factor PU box binding-1 (Pu.1) binds to a distal regulatory region (-
593 to -520) of the Tspo promoter. Pu.1 is a member of the Ets family of 
transcription factors, and its deficiency in animals leads to a complete lack of B 
cells, monocytes and tissue macrophages including Kupffer cells and microglia 
(Crotti and Ransohoff, 2016). Pu.1 binds to purine rich sequences containing a 
5’-GGAA/T-3’ core and induces a myeloid-specific gene expression signature 
(Nerlov and Graf, 1998; Weigelt et al., 2007, 2009). It is therefore conceivable 
that Pu.1 binding to the promoter might partly explain the Tspo specific 
expression pattern observed in microglia and other myeloid lineage cells during 
pathophysiological conditions (Rashid et al., 2018a).   
Similarly, the current study provides evidence that Ap-1 (cJun/cFos), Stat3, Sp1, 
Sp3 and Sp4 are bound to their respective cis-elements in the distal regulatory 
region (-593 to -520) of the Tspo promoter. In addition, stimulation of BV-2 cells 
with LPS led to an additional recruitment of the aforementioned transcription 
factors, including Pu.1 (excluding Stat3) to the Tspo promoter. Of note, previous 
studies have demonstrated that these transcription factors are activated in 
response to inflammatory stimuli resulting in the transcription of specific subsets 
of proinflammatory genes (Boutillier et al., 2007; Brightbill et al., 2000; Carver et 
al., 2013; Liu et al., 2015; Lodie et al., 1997). Interestingly, the transcription of 
such inflammatory response genes is regulated by a proximal promoter and, for 
most or all genes, one or more distant regulatory regions (Smale, 2010; Smale 
and Natoli, 2014). These distant promoter sequences are bound by multiple 
transcription factors in response to diverse inflammatory stimuli, and this process 
is critical for the selective activation of these genes (Smale, 2010; Smale and 
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Natoli, 2014). Take the human IFNβ gene for instance, an inflammatory response 
gene whose regulatory region consists of a short 55 bp DNA sequence (Thanos 
and Maniatis, 1995). Inflammatory stimuli such as a virus infection induces the 
recruitment and binding of a multitude of inducible transcription factors including 
NF-kB, IRF3, IRF7, ATF-2 and c-Jun to activate transcription (Smale, 2010; 
Thanos and Maniatis, 1995). Therefore, based on the findings of the current study 
that LPS-induced transcription of Tspo is strongly dependent upon a distal 
regulatory region and the recruitment of multiple inflammation responsive 
transcription factors, it is reasonable to speculate, at least in immune cells, that 
the underlying physiological function of Tspo may involve the subtle and complex 
mediation of the inflammatory response (Rashid et al., 2018a).  
However, despite observations in the current study that LPS stimulation induced 
the recruitment of Pu.1, Ap-1 and Sp family of GC-box binding transcription 
factors to the Tspo promoter, their precise role in mediating LPS-induced 
expression of Tspo remains largely elusive. Nonetheless, we show herein that 
the dimeric transcription factor Ap-1 (cJun/cFos) is essential for the upregulation 
of Tspo expression in BV-2 microglia following LPS stimulation. Consistently, 
previous research has also demonstrated that siRNA-mediated gene silencing of 
the Ap-1 subunit, cJun, is sufficient to significantly reduce Tspo levels in MA-10 
leydig and NIH-3T3 mouse fibroblasts cells (Batarseh et al., 2011). However, in 
the current study, single knockdown of either cJun or cFos did not inhibit basal 
nor LPS-induced Tspo expression in microglia. Our results also provide no 
insights into the mechanisms of Ap-1-mediated induction of Tspo expression in 
LPS-stimulated BV-2 cells. However, it is noteworthy that Ap-1 has previously 
been shown to play a fundamental role in the maintenance of chromatin 
“accessibility”, and by extension, the recruitment of inducible transcription factors 
to the chromatin (Biddie et al., 2011). Therefore, whether Ap-1 plays a similar role 
in the regulation of inducible Tspo expression in microglia by binding to its specific 
cis-element within the distal regulatory region and maintaining an open chromatin 
configuration for the recruitment of Pu.1 and Sp factors remains to be determined. 
Notwithstanding this uncertainty, findings from the current study showing that 
deletion or substitution mutation of the Ap-1-site in the distal promoter 
significantly inhibited basal and LPS induced Tspo promoter activity further 
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highlights the importance of Ap-1 in the regulation of Tspo in microglia (Rashid et 
al., 2018b).   
The TSPO proximal promoter, spanning approximately 150 bp upstream of the 
TSS, is situated in a CpG island and is very well conserved among humans, rats 
and mice (Batarseh and Papadopoulos, 2010). Sequence comparison of mouse 
and rat proximal promoters reveals up to 90% homology while that of mouse and 
human reveals approximately 70% homology (Batarseh and Papadopoulos, 
2010). Findings from the current study indicated that this proximal promoter 
retains very low basal activity in BV-2 microglia cells, in contrast to ARPE-19 cells 
where it was highly active and accounted for most of the promoter activity 
observed in this cell line. Previous studies have demonstrated that in MA-10 
leydig and Y1 adrenocortical cells which display high constitutive Tspo 
expression similar to ARPE-19 cells, this region constitutes the minimal promoter 
and contains all sequence components necessary for Tspo transcription initiation 
(Giatzakis and Papadopoulos, 2004). Bioinformatic analyses of the Tspo 
proximal promoter revealed the presence of four GC boxes, corroborating a 
previous report (Giatzakis and Papadopoulos, 2004). To analyze the importance 
of these GC boxes in regulating Tspo expression in ARPE-19 and BV-2 cells, we 
used siRNA to selectively down-regulate the expression of GC box binding 
factors Sp1, Sp3 or Sp4 either singly or in combination. Consistent with our prior 
findings showing high activity of the proximal promoter in ARPE-19 cells, 
individual knockdown of Sp3 or Sp4 and double knockdowns of Sp1/Sp3, 
Sp1/Sp4 or Sp3/Sp4 significantly reduced TSPO protein expression in ARPE-19 
cells but not in BV-2 microglia. To verify that the GC box binding Sp factors were 
important in cell-line specific activation of Tspo transcription, the effect of the 
histone deacetylase inhibitor, TSA, on Tspo promoter activity in BV-2 and ARPE-
19 cells was assessed. TSA has been shown in previous studies to augment 
promoter activity by enhancing the recruitment of Sp1 and Sp3 to GC boxes 
(Schnur et al., 2007). Moreover, treatment of MDA-MB-231 cells with TSA has 
been shown to strongly induce TSPO promoter activity via GC-rich elements 
within the proximal promoter, with the overexpression of Sp1 and Sp3 
potentiating TSA effects (Batarseh et al., 2012b). In the current study, we 
demonstrate that TSA treatment strongly activates the Tspo promoter in ARPE-
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19 cells but not in BV-2 microglia cells. Altogether, these results indicate that the 
proximal promoter harboring a series of GC boxes as binding sites for Sp factors 
is sufficient for the effective activation of TSPO transcription in RPE cells, but not 
in microglia where additional distal elements and factors are required to activate 
transcription. Furthermore, these findings indicate that distinct regions of the 
promoter direct constitutive and inducible transcription of Tspo. Indeed, 805 bp 
upstream of the TSS are required for near maximal promoter activity in NIH-3T3 
cells whose Tspo expression can be induced by phorbol-12-myristate 13-acetate 
(PMA), in contrast to 123 bp required for most promoter activity in MA-10 cells 
which display high constitutive levels of Tspo that is non-responsive to PMA 
stimulation (Batarseh et al., 2008; Giatzakis and Papadopoulos, 2004).    
Despite the weak activity of the proximal promoter in BV-2 microglia cells, 
deletion of sequences between -168 to -39 led to a significant loss in promoter 
activity to levels slightly above background measured using the promoterless 
plasmid. Likewise, mutagenesis of the GC boxes located in the proximal promoter 
or siRNA-mediated knockdown of Sp factors resulted in significant decreases in 
promoter activity in BV-2 and RAW 264.7 cells. Mutations within the overlapping 
GC boxes caused the greatest decrease in promoter activity (90-95%) in both cell 
lines. Given that the TSPO promoter, similar to housekeeping genes, lacks TATA 
and CCAAT boxes, the observation that disruption of proximal GC boxes 
significantly diminished promoter activity was to be expected (Azizkhan et al., 
1993). Previous research has demonstrated that GC boxes and Sp factors are 
critical for the initiation of transcription in promoters that lack TATA and CCAAT 
motifs (Azizkhan et al., 1993). Consistently, our findings from ChIP analyses 
confirmed that the GC boxes in the proximal promoter are bound by Sp1, Sp3, 
and Sp4, and that additional recruitment of these transcription factors to the 
promoter occurs as part of a series of events that facilitate the inducible 
expression of Tspo in microglia in response to inflammatory stimuli such as LPS 
(Rashid et al., 2018b).   
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5.0 Conclusion and future perspectives 
In summary, findings of the current study show that a 845 bp fragment upstream of the 
transcription initiation site constitutes the minimal Tspo promoter sufficient to drive full 
transcriptional activity in BV-2 microglia cells. The present findings further indicate that 
a complex interplay between proximal and distal promoter elements within the 845 bp 
fragment exists to regulate Tspo expression in BV-2 microglia (Figure 22). Additionally, 
results presented herein reveal the presence of a strong positive distal regulatory 
region, spanning from -593 to -520 relative to the TSS, that is bound by Ap-
1(cJun/cFos), Pu.1, Stat3 and Sp factors and whose deletion abolishes basal as well 
as LPS induced promoter activity. Moreover, the current results indicate that LPS-
induced Tspo expression in BV-2 cells is mediated, at least in part, at the transcriptional 
level via the additional recruitment of Pu.1, Ap-1 (cJun/cFos), Sp1, Sp3 and Sp4 factors 
to the distal and proximal regulatory sequences. Notably, we show that the dimeric 
transcription factor Ap-1 (cJun/cFos) is indispensable for LPS-induced Tspo 
expression in BV-2 microglia cells. Consistent with the presence of important distal 
elements, we demonstrate that the proximal region extending -125 bp upstream of the 
TSS which contains four GC-boxes is necessary but insufficient to support basal or 
LPS-induced Tspo promoter activity in BV-2 cells. In contrast, the sequence elements 
contained in the proximal promoter are sufficient to drive full promoter activity in ARPE-
19 cells. Taken together, these findings provide new insights into the molecular 
mechanisms responsible for Tspo regulation in BV-2 microglia during basal as well as 
LPS-induced inflammatory conditions. In addition, findings presented herein suggest 
that important distal elements may account for the cell-specific differences in Tspo 
expression patterns between BV-2 microglia and ARPE-19 cells.    
However, while the current findings are extensive and serve as a good starting point 
for the identification of signaling pathways via which TSPO is overexpressed, they only 
partially explain how Tspo regulation is achieved in microglia and leave a lot of open 
questions to be addressed in the future. Examples of these questions include; i) How 
do the identified transcription factors interact with chromatin structure and enhancer 
landscapes to selectively regulate Tspo expression in microglia? ii) Is the promoter 
region -593 to -520, shown herein to be bound by lineage and signal dependent 
transcription factors, a functional enhancer that can activate Tspo transcription 
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independent of orientation and position relative to the TSS? iii) Are there other distant 
enhancers that are involved in the transcriptional activation of TSPO in microglia in 
response to noxious stimuli in the CNS? To what extent are these findings translatable 
to murine microglia in-vivo or to human microglia?  
New genetic tools and techniques can be used to address some of these questions. 
For instance, the CRISPR/Cas9 system can be used to generate mice with defined 
point mutations in the genome and subsequently examine the relevance of the in-vitro 
findings presented herein. New genome-wide approaches such as Hi-C could also be 
used to unravel the complex enhancer(s)-promoter interactions that are responsible 
for coordinating changes in TSPO transcription in microglia in response to 
inflammatory stimuli. High-throughput technologies such as Chromatin 
immunoprecipitation sequencing (ChIP-seq) can be adopted to identify more distant 
regulatory elements. Consequently, deciphering the mechanisms involved in TSPO 
regulation in microglia is likely to yield information about the protein’s function which 
currently remains unknown as well as aid current efforts to selectively target TSPO for 
immunotherapeutic benefit.  
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Figure 22: Schematic representation of cis-elements and transcription factors 
regulating Tspo gene transcription in BV-2 microglia during physiological and LPS-
induced pathophysiological conditions. Pu.1, Ap-1 (cJun/cFos), Stat3, Sp1, Sp3 and Sp4 
factors binding proximal and distal elements on the Tspo promoter work in concert to regulate 
Tspo transcription. Pathological stimulus such as LPS induces an enhanced recruitment of 
these factors to the promoter to augment transcription, resulting in strongly upregulated Tspo 
levels in Microglia (Rashid et al., 2018b).  
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